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1.1. Purpose of the guidelines
Guidelines driven by scientific societies on vascular graft/
endograft infection (VGEI) have not been published. The Eu-
ropean Society for Vascular Surgery (ESVS) has developed
clinical practice guidelines for the care of patients with VGEI.
The aim of this document is to assist physicians involved in the
diagnosis and treatment of patients with VGEI in selecting the
bestmanagement strategy indifferent scenarios.Thepotential
users of this guideline include angiologists, vascular, cardio-
vascular and general surgeons, infectious disease physicians,
and radiologists, and the target population comprises patients
with VGEI in the supra-aortic trunks, thoracic and/or abdom-
inal aorta, and peripheral arteries.
Guidelines have the purpose of promoting a standard of
care according to specialists in the field, in this case rep-
resented by members of the ESVS. However, under no cir-
cumstances should these guidelines be seen as the legal
standard of care in all patients. As the word guidelines
states in itself, the document is a guiding principle, but the
care given to a single patient is always dependent on the
individual (symptom variability, comorbidities, age, etc.) and
treatment setting (techniques available, local expertise).Table 1. Level of evidence
Level of
evidence A
Data derived from multiple randomized
clinical trials or meta analyses.
Level of
evidence B
Data derived from a single randomized
clinical trials or large non-randomized
studies.
Level of
evidence C
Consensus of opinion of the experts
and/or small studies, retrospective
studies, registries.1.2. Methods
1.2.1. The writing committee. The members of this guide-
lines Writing Committee (WC) were selected by the ESVS,
the European Association of Nuclear Medicine (EANM), and
the Groupe de Recherche sur les Infections de Prothèses, to
represent physicians involved in the management of pa-
tients with VGEI. They include vascular surgeons, radiolo-
gists, and infectious disease specialists. WC members have
provided disclosure statements of all relationships that
might be perceived as real or potential sources of conflicts
of interest, which are kept on file at the ESVS headquarters.
No ESVS reviewers or individual WC members received any
financial support from third parties in direct or indirect
relation to this guideline, and all WC members and re-
viewers signed declarations of interest.
1.2.2. Evidence collection
1.2.2.1. Search strategy. The purpose, list of topics, and tasks
and methods regarding the construction of the guidelines
were agreed and distributed among the WC members in an
initial meeting held in Strasbourg on 30 June 2017.
1.2.2.2. Literature search and selection. All WC members
performed a systematic literature search strategy for each
of their assigned sections, carried out in PubMed, Scopus,Cardiosource Clinical Trials Database, and the Cochrane Li-
brary databases, first from January 1997 to November 2017,
with a later update to February 2019 for relevant papers
published in English. Reference checking and a hand search
added other relevant literature. Abstracts were excluded.
Single case reports or case series were included if they were
of paramount importance to these guidelines to enlighten
the manuscript.
Selection of the literature was performed based on in-
formation provided in the title and abstract of the retrieved
studies. Only peer reviewed published literature and studies
presenting pre-defined outcomes were considered. The
selection process followed the pyramid of evidence, with
aggregated evidence at the top of the pyramid (systematic
reviews, meta-analysis), followed by randomised controlled
trials (RCTs), then observational studies, leaving expert
opinion at the bottom. The level of evidence per section in
the guidelines is dependent on the level of evidence avail-
able on the specific subject.
1.2.2.3. Evidence and recommendation grading criteria. To
definethecurrentguidelines,membersof theWCreviewedand
summarised the selected literature. Conclusions were drawn
based on the availability and quality of the scientific evidence,
and recommendations for the evaluation and treatment of
patientswithVGEIwere formulatedbasedon theanalysis of the
evidence and through consensus when evidence was scarce.
The European Society of Cardiology (ESC) grading system
was used for evidence and recommendation rating.The letter
A, B, or C reflects the level of current evidence (Table 1), and
weighing the level of evidence and expert opinion, each
recommendation is graded as class I, IIa, IIb, or III (Table 2).
For those recommendations tables of evidence were built
and are available as supplementary material.
1.2.2.4. The patient’s perspective. The goals behind patient
participation in healthcare decision making can be cat-
egorised as democratisation and increased quality of de-
cisions. Patient engagement improves the validity of clinical
guidelines and is encouraged by international and national
groups. In order to better understand patient feedback,
Table 2. Classes of recommendations
Classes of
recommendations
Definition
Class I Evidence and/or general agreement that a
given treatment or procedure is beneficial,
useful, effective.
Class II Conflicting evidence and/or a divergence
of opinion about the usefulness/efficacy
of the given treatment or procedure.
Class IIa Weight of evidence/opinion is in favour of
usefulness/efficacy.
Class IIb Usefulness/efficacy is less well established
by evidence/opinion.
Class III Evidence or general agreement that the
given treatment or procedure is not
useful/effective, and in some cases may
be harmful.
344 Nabil Chakfé et al.European patients were interviewed: representatives of
patient associations in the field of aortic dissection and
infectious diseases; and patients treated for abdominal VGEI
(patients operated on by surgeons of the WC). The main
questions that arose from discussions were: (1) Did you feel
your physician provided enough information about the risk
of infection at the time of the initial procedure? (2) What
did you think about the management once the diagnosis of
VGEI was made? and (3) Did you think that your physician
provided enough information on the risks related to VGEI?
Patients were interviewed with a focus on these three open
questions.
1.2.3. The revision process. The guidelines document,
merged and harmonised by the co-chairmen of the WC, un-
derwent internal review. Once approved by every WC mem-
ber, it moved on to external revision by the ESVS Guidelines
Committee (GC) members and chosen external experts in the
field. Each draft was revised by the WC and the final docu-
ment, approved by all WC and GC members and external re-
viewers, was submitted to the European Journal of Vascular
and Endovascular Surgery on 20 July 2019.
1.2.4. The update plan. As technology and disease knowl-
edge in this field changes rapidly, current recommendations
can become outdated. It is an aim of the ESVS to revise the
guidelines when important new insights in the evaluation
and management of VGEI become available or every five
years at the latest.2. GENERAL CONSIDERATIONS
2.1. Definition of incisional surgical site infection
Studies dealing with VGEI are mostly case series rather than
randomised studies. Diagnosis of VGEI is usually related to
clinical findings, imaging studies, and microbiological exami-
nations.1 Criteria for incisional surgical site infections (SSI),
which can be both superficial and deep, have been described
by the Centers for Disease Control and Prevention (CDC) and
can be applied to the description of VGEI (Table 3).22.2. Classifications
While the CDC definitions2 differentiate between superficial
and deep incisional SSIs without placing emphasis on vascular
grafts (VGs), the Szilagyi classification and the Samson classi-
fication specifically also consider VG involvement, while the
extent of graft involvement can be described using the Bunt
classification (Table 4).3e5 Furthermore, aortic VGEI can also
be divided into early (< 4months) or late (> 4months) onset,
which, in many cases, is also extrapolated to other VGEl.6
However, the clinical relevance of differentiation between
early and late infections remains a matter of debate.
2.3. Definition of vascular graft/endograft infection
To overcome the numerous shortcomings of current clas-
sifications, the Management of Aortic Graft Infection
(MAGIC) group has developed a list of major and minor
criteria with respect to clinical, surgical, radiological, and
laboratory findings (Table 5).1 Once VGEI is suspected, an
exhaustive evaluation of the clinical status, signs of infec-
tion, and comorbidities of the patient according to the
MAGIC criteria is recommended.
According to the MAGIC criteria, VGEI is suspected in the
presence of one major or two minor criteria of the three
different categories, and VGEI is diagnosed when there is at
least a single major criterion and any other criterion from
another category. For example, a fever  38C is considered
non-specific for VGEI and therefore it is required that no
other clinical cause is apparent. Sepsis and systemic in-
flammatory response syndrome may be caused by some-
thing other than VGEI and is defined as combinations of
different findings. Anorexia, lethargy, and malaise may
accompany aortic graft and endograft (EG) infection, but are
also considered insufficiently specific.1 Intra-operative fluids
around a graft can represent pus, but despite a yellowish or
cloudy appearance may be present for non-infective rea-
sons and microbiological culture will be negative. Therefore,
pus cells must be proven by direct microscopy to be
considered a major criterion. Furthermore, a direct
communication between non-sterile sites and a prosthesis
indicates graft infection: aorto-enteric fistula (AEnF), aorto-
bronchial fistula (ABF), deployment of a stent graft in an
already infected field (e.g., infected aneurysm), and
exposed grafts in deep open wounds.
2.4. Epidemiology
2.4.1. Incidence. VGEI are usually multifactorial and result
from the complex involvement of patient, surgical, and
environmental factors, making the real incidence difficult to
assess. Reported incidences of VGEI by type and anatomical
location will be developed in specific sections.
2.4.2. Risk factors. Multiple risk factors contribute to VGEI
and are listed in Table 6.
2.5. Pathogenesis
The pathogenesis of VGEI is multifactorial. Presumably,
early VGEI are mostly caused by a breach in sterility during
Table 3. Centers for Disease Control and Prevention criteria for superficial and deep surgical site infections (SSI)2
Criteria Superficial SSI Deep SSI
Diagnostic criteria*
1 Infection occurs within 30 days after the operative procedure Infection occurs within 30 days after the operative
procedure if no implant is left in place, or within one
year if implant is in place and the infection appears
to be related to the operative procedure
and 2 Infection involves only skin and subcutaneous tissue of
the incision
Infection involves deep soft tissues (e.g., fascia and
muscle layers) of the incision
and 3 Patient has at least one of the following: Patient has at least one of the following:
 Purulent drainage from the superficial incision  Purulent drainage from the deep incision but not
from the organ/space component of the surgical site
 Organisms isolated from an aseptically obtained culture of
fluid or tissue from the superficial incision
 A deep incision spontaneously dehisces or is
deliberately opened by a surgeon and is culture
positive or not cultured when the patient has at
least one of the following signs or symptoms: fever
(>38C), or localised pain or tenderness. A culture
negative finding does not meet this criterion
 At least one of the following signs or symptoms of
infection: pain or tenderness, localised swelling, redness
or heat, and superficial incision is deliberately opened by
surgeon and is culture positive or not cultured. A culture
negative finding does not meet this criterion
 An abscess or other evidence of infection involving
the deep incision is found on direct examination,
during re-operation, or by histopathological or
radiological examination
 Diagnosis of superficial incisional SSI by a surgeon or
attending physician
 Diagnosis of a deep incisional SSI by a surgeon or
attending physician
Types
Incisional
primary
A superficial incisional SSI that is identified in the primary
incision in a patient who has had an operation with one or
more incisions
A deep incisional SSI that is identified in a primary
incision in a patient who has had an operation with
one or more incisions
Incisional
secondary
A superficial incisional SSI that is identified in the secondary
incision in a patient who has had an operation with >1
incision (e.g., donor site [leg] incision to harvest autologous
veins for in situ reconstruction of an abdominal vascular graft
infection)
A deep incisional SSI that is identified in the secondary
incision in a patient who has had an operation with >1
incision (e.g., donor site [leg] incision to harvest
autologous veins for in situ reconstruction of an
abdominal vascular graft infection)
Reporting instructions
Do not report a skin suture abscess with minimal
inflammation and discharge confined to the points of suture
penetration, as an infection
Classify infection that involves both superficial and
deep incision sites as deep incisional SSI
Do not report a localised stab wound infection as SSI; instead,
report as skin or soft tissue infection, depending on its depth
If the incisional site infection involves or extends into the fascial
and muscle layers, report as a deep incisional SSI
* For diagnosis of SSI, diagnostic criteria 1, 2, and 3 must all be true.
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thrombus, while late VGEI are mostly caused by haema-
togenous seeding from a bacteraemia (mostly arising from
the urinary or respiratory tract), or from bacterial trans-
location or iatrogenic contamination during catheter-
isation.6e8 The pathogenesis of AEnF, aorto-oesophageal
(AEsF), and ABF remains unclear. Ischaemia of the visceral
wall due to occlusion of the feeding arteries, and me-
chanical erosion by the aneurysm or of a suture line
pseudo-aneurysm, especially when still under pressure due
to presence of an endoleak, have all been suggested. Fistula
can occur as a result of direct trauma related to surgical
injury, poor tunnelling, erosion by direct contact, or by the
penetration of an oversised EG. Previous adjacent or
remote infection in any site is considered to be a causative
or contributing factor.9,10
The quality of material incorporation related to tissue
ingrowth and healing also plays a role, explaining that VEGImight even be more frequent than VG infection (VGI), as
there is no tissue ingrowth in the wall of the EG fabric that is
surrounded only by thrombotic material, contrary to VG.112.6. Clinical presentation
As mentioned in the MAGIC criteria, the clinical presenta-
tion of patients with VGEI varies between mild symptoms
(redness of the skin, non-purulent effusion from a wound)
to severe and evident symtoms such as sepsis or anasto-
motic rupture with hypovolaemic shock.1 Fever of unclear
origin and an unexplained leukocytosis with concomitant
increase of C reactive protein (CRP) and fever may be the
only clinical or laboratory sign of VGEI. In other cases the
clinical manifestations may include abscess, mass, septic
embolisation, septic shock, bleeding, melaena, haematem-
esis, haematuria, ileus, or abdominal distension. When VGEI
is suspected, a complete clinical and biochemical evaluation
Table 4. Classifications for wound and vascular graft infections with respect to wound infection (Szilagyi, Samson) and to the extent
of graft involvement (Bunt)3e5
Szilagyi classification:
Grade I: cellulitis involving the wound
Grade II: infection involving subcutaneous tissue
Grade III: infection involving the vascular prosthesis
Samson classification:
Group 1: no deeper than dermis
Group 2: subcutaneous tissue, no direct contact with the graft
Group 3: body of graft but not anastomosis
Group 4: exposed anastomosis, no bleeding, no bacteraemia
Group 5: anastomosis involved, bleeding, bacteraemia
Extent of graft involvement (Bunt classification modified)
Peripheral graft infection:
P0 graft infection: infection of a cavitary graft (e.g., aortic arch; abdominal and thoracic aortic interposition; aorto-iliac, aortofemoral,
iliofemoral graft infections)
P1 graft infection: infection of a graft whose entire anatomical course is non-cavitary (e.g., carotidesubclavian, axillo-axillary,
axillofemoral, femorofemoral, femorodistal, dialysis access bridge graft infections)
P2 graft infection: infection of the extracavitary portion of a graft whose origin is cavitary (e.g., infected groin segment of an
aortofemoral or thoracofemoral graft, cervical infection of an aortocarotid graft)
P3 graft infection: infection involving a prosthetic patch angioplasty (e.g., carotid and femoral endarterectomies with prosthetic patch
closure)
Graft-enteric erosion
Graft-enteric fistula
Aortic stump sepsis after excision of an infected aortic graft
346 Nabil Chakfé et al.of the patient is required in order to provide a sufficient
analytical overview.12
Post-implantation syndrome, characterised by transitory
fever associated with elevated leukocytes and CRP may be
observed following endograft implantation, but might also
be distinguishing from an actual infection.13Table 5. The MAGIC classification1
Criterion Clinical/surgical Radiology
Major
Pus (confirmed by microscopy) around
graft or in aneurysm sac at surgery
Perigraft fluid
after insertion
Open wound with exposed graft or
communicating sinus
Perigraft gas o
after insertion
Fistula development, e.g., aorto-enteric
or aortobronchial
Increase in
demonstrated o
Graft insertion in an infected site, e.g.,
fistula, mycotic aneurysm, or infected
pseudo-aneurysm
Minor
Localised clinical features of graft
infection, e.g., erythema, warmth,
swelling, purulent discharge, pain
Other, e.g., su
fluid soft
aneurysm expa
formation:
thickening;
suspicious met
PET/CT; rad
uptake
Fever 38C with graft infection as
most likely cause
CT ¼ computed tomography; FDG-PET/CT ¼ 18F-fluoro-D-deoxyglucose2.7. Microbiology and sampling techniques
2.7.1. Microbiology. Micro-organism identification is a key
issue in order to provide the patient with the best treat-
ment. Using the different available sampling techniques,
micro-organisms can be isolated in about 75% e 98% of
cases.14e16 Responsible pathogens are Gram positiveLaboratory
on CT scan  3 months Organisms recovered from an
explanted graft
n CT scan  7 weeks Organisms recovered from an intra-
operative specimen
perigraft gas volume
n serial imaging
Organisms recovered from a
percutaneous, radiologically guided
aspirate of perigraft fluid
spicious perigraft gas/
tissue inflammation;
nsion; pseudo-aneurysm
focal bowel wall
discitis/osteomyelitis;
abolic activity on FDG-
iolabelled leukocyte
Blood culture(s) positive and no
apparent source except graft infection
Abnormally elevated inflammatory
markers with graft infection as most
likely cause, e.g., erythrocyte
sedimentation rate, C reactive protein,
white cell count
positron emission tomography/computed tomography
Table 6. Risk factors for vascular graft/endograft infection6,7
Pre-operative risk factors
Prolonged pre-operative hospitalisation
Infection in a remote or adjacent site
Recent percutaneous arterial access at the implant site
Emergency/urgent procedure
Re-intervention
Lower limb infection (ulcer, gangrene, cellulitis)
Groin incision
Intra-operative risk factors
Breach in aseptic technique
Prolonged operation time
Concomitant gastrointestinal or genitourinary procedure
Post-operative risk factors
Post-operative wound complications (infection, skin necrosis,
lymphocoele, seroma, haematoma)
Graft thrombosis
Patient related risk factors/altered host defences
Malignancy
Lymphoproliferative disorder
Immune disorders
Corticosteroid administration
Chemotherapy
Malnutrition
Diabetes mellitus/peri-operative hyperglycaemia
Chronic renal insufficiency/end stage renal disease
Liver disease/cirrhosis
Immunosuppression by non-suspended anti-tumour necrosis
factor alpha
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Staphylococcus aureus, and coagulase negative staphylo-
cocci); Gram negative bacteria account for about 34% of
VGEIs and and anaerobes 8%.14e17
In a recent meta-analysis, the risk of re-infection has been
studied according to different infecting micro-organisms.17
Staphylococcus aureus, Enterobacteriaceae, Pseudomonas
aeruginosa, and beta haemolytic streptococci were classi-
fied as virulent, while bacteria belonging to the skin colo-
nising flora such as Staphylococcus epidermidis,
corynebacterial, and Cutibacterium acnes were classified as
non-virulent agents. The results of this meta-analysis
established that virulent organisms were significantly
associated with an increased risk of re-infection.
Antimicrobial resistance of the causative bacteria is
another factor that may reduce the chance of healing, but
this relationship has not been clearly established in the
setting of VGEIs.14
The susceptibility of bacteria to the few antibiotics that
exhibit a sustained activity in the environment of a biofilm
(e.g., rifampicin combinations for staphylococcal implant
infections) is another element that may lead to re-infection
in patients treated for VGEIs.18e20
2.7.2. Sampling techniques. Microbiological samples
may support establishing the diagnosis of a VGEI. Ideally
samples should be harvested before the start of antimi-
crobial therapy. However the accuracy and relevance
of microbiological tests depend on whether specimens werecollected without contamination, and in an adequate
quantity.21 Moreover, samples should be forwarded quickly
to the microbiology laboratory. If they cannot be forwarded
immediately they should be stored at þ4C.
2.7.2.1. Directly obtained specimens. Meaningful results
will be achieved with specimens obtained directly from the
suspected infection site. These may include surgically
explanted prosthetic materials, intra-operatively obtained
tissue and graft biopsies from the infected area, or at least
three samples from perigraft fluid collection.22 Paediatric
anaerobic tubes, which require very small amounts of ma-
terial, can be used.
Aspirated specimens obtained under ultrasound (US) or
computed tomography (CT) guidance provide material for
an accurate microbiological diagnosis. The presence of
graft incorporation into tissue reliably excluded the pres-
ence of bacteria in cultures in 97% of investigated grafts,
whereas the finding of graft disincorporation accurately
predicted a positive culture in 89% of all positive VGEI
cases.23 In general, tissue specimens or a portion of the
graft material are superior to swab specimens of infected
sites, even when collected using a sterile technique intra-
operatively. At least three direct specimens should be
collected in sterile containers.22 Swabs should be avoided
because they do not allow differentiation of colonising
micro-organisms from true pathogens and may lead to
overprescription of broad spectrum antibiotics. Swabs
have an inherent difficulty transferring bacteria or fungi
from the swab fibres onto culture media, and because the
inoculum from the swab often is not uniformly distributed
across several different agar plates.24 If swabs are used,
the type of swab should be selected on basis of its ability
to collect micro-organisms. Polyethylene terephthalate
(PET) swabs should be used.
A new innovative specimen collection technology
(microDTTect) could help in the future, as it allows for
contamination free sampling, and also it can dislodge bac-
teria embedded in a biofilm from prosthetic surfaces.25
2.7.2.2. Indirectly obtained specimens. Indirect specimens
might also be meaningful, especially when direct specimens
are not collected in cases when redo surgery is not per-
formed. Such speciments include blood cultures, specimens
obtained from a superficial wound, a draining sinus, or
otherwise close anatomical structures.
Despite being an indirect microbiological sampling
method, blood cultures may yield supportive information,
as pre-operative blood cultures have been found to be
positive in about 35% of cases and both pre- and peri-
operative samples are positive for the same micro-
organism in about 22% e 30% of cases.14,15
However, other indirectly obtained specimens using
swabs, biopsy samples or aspirates obtained from a
superficial wound, a draining sinus, or otherwise close
anatomical structures always contain skin flora or
colonisation, and might not accurately reflect the
causative micro-organism of a VGEI.26 Bacteriological
348 Nabil Chakfé et al.investigation of negative pressure wound therapy
(NPWT) foams should not be performed to support the
diagnosis of a VGEI because of the low sensitivity and
specificity.27
Therefore, results from indirectly obtained specimens
should be considered with caution.
2.7.3. Microbiological sample processing. Specimens may
be investigated using different techniques such as direct
streaking specimens on agar plates, placing specimens
into broth culture, homogenisation of tissue or graft
specimens with serial dilution techniques, sonication
of a harvested graft, or vortex mixing tissue samples in
order to enhance the recovery of biofilm forming micro-
organisms.28
Enhanced sample processing techniques such as vortex
mixing specimens or sonication improve the detection
rate of microorganisms attached to graft material.28e30
One study found that ultrasonic bath treatment
released consistently more bacteria than direct ultrasonic
disruption or vortex agitation.31 Importantly, the high
energy levels of direct ultrasonic disruption can decrease
the number of viable Gram negative bacteria, and vortex
agitation consistently produced the lowest bacterial
numbers among the three methods tested. An ultrasonic
bath treatment of one to five minutes duration of
infected VG at a frequency of 25 e 40 KHz may be the
optimal preparation method for causative bacteria
detection.31 Adding broad range polymerase chain reac-
tion (PCR) detection to sonicated fluid cultures may even
increase the detection rate of bacteria attached to graft
material.32
2.8. Imaging modalities
2.8.1. Introduction. Various imaging techniques are used
in the diagnostic work up when VGEI is suspected. Con-
ventional imaging techniques such as US, CT, CT with
angiography (CTA), and magnetic resonance with angiog-
raphy (MRA) are used most frequently. Other available
imaging tools are nuclear medicine techniques, such as 18F-
fluoro-D-deoxyglucose positron emission tomography (18F-
FDG-PET) with or without diagnostic contrast enhanced CT
(18F-FDG-PET/CT), and white blood cell scintigraphy
(WBCS), that can be combined with single photon emission
computed tomography (SPECT/CT) for better localisation of
the infection.33
2.8.2. Conventional techniques
2.8.2.1. Ultrasound. US is the most common, non-invasive,
low cost imaging modality to identify findings associated
with VGEI.
US characteristics of VGEI are the presence of pseudo-
aneurysm, sustained presence of gas (if still present after
> 7 weeks), and purely anechoic fluid collections (if still
present >3 months after surgery).33,34 It can differentiate
between haematoma or abscess formation, which makes it
a good primary imaging screening modality, especially for
superficial peripheral VG. However, the absence of peri-prosthetic collections on US does not allow ruling out of a
VGEI. US also allows investigating for graft thrombosis,
which can be the first sign of VGEI, and it can guide
puncture for bacteriological purposes.14,33,35
However, US has a high interoperator variability and
the predictive value is limited in the case of a centrally
located graft due to overlying bowel gas or obesity.14,34
Therefore, the sensitivity of US for the diagnosis of VGEI
is considered as low, and additional investigations are
often needed to obtain more detailed information on VG
status.
2.8.2.2. Computed tomography angiography. CTA has been
considered the reference imaging standard in diagnosing
VGEI for a long time, as it is able to visualise the charac-
teristic features of VGEI.33 The use of intravenous contrast,
with images acquired in the arterial phase, may show
certain signs such as ectopic gas, fluid, soft tissue
enhancement, pseudo-aneurysm, focal bowel thickening,
and discontinuation of the aneurysmal wall, all of which can
all be used as criteria to increase the likelihood of a VGEI.36
Furthermore, in the arterial phase it may be possible to
detect contrast passage from the aorta to the digestive tract
in cases of AEnF.33
Although better than US, CTA sensitivity and specificity
remains moderate and variable.34 In a systematic review
and meta-analysis of patients with suspected VGEI, the
pooled sensitivity of CTA in diagnosing VGEI was 0.67
(95% confidence interval [CI] 0.57 e 0.75) and the pooled
specificity was 0.63 (95% CI 0.48 e 0.76). This meta-
analysis showed that an isolated CTA does not provide
enough evidence to establish the diagnosis of VGEI
(Fig. 1).37
Standalone CTA can confirm the diagnosis of VGEI, but a
second imaging modality such as 18F-FDG-PET/CT or WBCS
combined with SPECT/CT may be useful to map the extent
of the infection.
2.8.2.3. Magnetic resonance angiography. MRA has not
been evaluated as extensively as CTA for the diagnosis of
VGEI, but several studies have suggested that MRA offers
better anatomical and functional information than CTA,
including tissue characterisation.14,35 Simultaneous or
sequential acquisition of 18F-FDG-PET with MRA pro-
vides additional quantitative molecular functional infor-
mation concerning the inflammatory lesion, and
accurate localisation, as well as anatomical changes with
motion correction. After six post-operative weeks, the
presence of collections with a hypo-intense signal in T1
and a hyperintense signal in T2 strongly suggests a
VGEI.14,35
In a series of patients with suspected aortic VGEI, the
sensitivity of MRA was 0.68 (95% CI 0.50 e 0.86), and the
specificity 0.97 (95% CI 0.91 e 1.00).38 However, owing to
low availability and long acquisition times resulting in mo-
tion artefacts, MRA is currently not used as a first line
diagnostic modality if VGEI is suspected.
2.8.3. Nuclear imaging techniques. Nuclear medicine im-
aging techniques, such as 18F-FDG-PET combined with (low
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Figure 1. Sensitivities and specificities for each imaging modality.37 CTA ¼ computed tomography angiography; TP ¼ true positive; FP ¼
false positive; FN ¼ false negative; TN ¼ true negative; CI ¼ confidence interval; FDG-PET ¼ 18F-fluoro-D-deoxyglucose positron emission
tomography/computed tomography; FDG-PET/CT ¼ 18F-fluoro-D-deoxyglucose positron emission tomography/computed tomography;
WBC ¼ white blood cell; SPECT/CT ¼ single photon emission computed tomography/computed tomography.
ESVS 2020 Management Guidelines for Vascular Graft and Endograft Infections 349dose or contrast enhanced) CT and WBCS combined with
SPECT/CT, incorporate anatomical and metabolic informa-
tion at the same time and are able to differentiate between
VGEI, soft tissue infection, and, in some cases, inflammation
by pattern recognition, heterogeneity, and intensity of up-
take with FDG-PET,39 and by increase in size or intensity
with time with WBCS.40
2.8.3.1. Positron emission tomography. 18F-FDG-PET imag-
ing is based on the uptake of radioactive labelled glucose incells/tissue with enhanced glucose metabolism, such as in-
flammatory cells and micro-organisms such as bacteria or
fungi. This diagnostic method may differentiate between peri-
prosthetic collection and involvement of the graft material
but should be combined with low dose CT for anatomical
correlation. Nowadays, 18F-FDG-PET is mainly performed in
hybrid mode with FDG-PET/CT, which has an established role
in the assessment of suspected VGEI, providing accurate
anatomical localisation of the site of infection.
350 Nabil Chakfé et al.The EANM and Society of Nuclear Medicine and Molec-
ular Imaging published procedural guidelines on how to
perform a 18F-FDG-PET scan for infectious purposes.41 As
the administered dose of 18F-FDG and time interval be-
tween the scan acquisition may cause heterogeneity be-
tween studies, the EANM launched a strategy to harmonise
18F-FDG-PET/CT studies (EANM Research Limited, EARL).42
There are different ways to analyse and interpret 18F-
FDG-PET/CT studies. The main interpretation criteria are the
calculated maximum standardised uptake value (SUVmax),
the tissue to background ratio, the pattern of uptake (focal/
diffuse), or the visual grading scale.41,43 It is suggested that
SUVmax > 8 in the perigraft area is the cut off value for
distinguishing infected grafts from non-infected grafts, but
this is based on a small number of patients. It is also
considered that linear, diffuse, and homogeneous uptake
with projection of the vessel is highly suggestive of infec-
tion. Although in the past diabetes and use of antibiotics
were supposed to degrade image quality, two recent
studies demonstrated that diagnostic accuracy was not
affected.44,45
In a meta-analysis, the sensitivity of single 18F-FDG PET
without combined low dose or contrast enhanced CT in
diagnosing VGEI in patients with a suspected VGEI was 0.94
(95% CI 0.88 e 0.98), with a specificity of 0.70 (95% CI 0.59
e 0.79).37 18F-FDG-PET combined with CT (adding low dose
or contrast enhanced CT) showed even better results, with a
sensitivity of 0.95 (95% CI 0.87 e 0.99) and a specificity of
0.80 (95% CI 0.69e 0.89) (Fig. 1).37
2.8.3.2. White blood cell scintigraphy. WBCS detects infec-
ted sites by visualizing the increase of accumulation of
radiolabelled white blood cells over time. Recently, proce-
dural guidelines for the labelling of the white clood cells, and
for the correct acquisition and interpretation criteria for
WBCS were published.40 The diagnosis of VGEI infection isDiagnostic imaging when
Thoracic/abdominal
CTA (MRA if CTA is contraindicated)
18F-FDG-PET/CT*
WBCS with SPECT/CT†
No other imagin
Figure 2. Imaging workflow if vascular graft/endograft infection (VG
CTA ¼ computed tomography angiography; MRA ¼ magnetic resonanc
tron emission tomography/computed tomography; WBCS ¼ white bloo
tomography/computed tomography. *18F-FDG PET/CT can add more
infection cases a second imaging modality as 18F-FDG PET/CT and/or W
the infection. yWBCS can be applied if available otherwise, 18F-FDG PEbased on the presence of pathological accumulation of
labelled white blood cells at the site of infection. At least two
sets of images are required (2 e 4 and 20 e 24 hours after
injection) and an increase in intensity or size with time is
considered positive for an infection.When positive, SPECT/CT
images are mandatory for exact localisation of the infection
(soft tissue only, graft, or extension).40
WBCS is a very specific method, but it has some limita-
tions. The procedure is time consuming and labour inten-
sive, as the imaging needs to be performed at least at two
different time points (preferably 2 e 4 and 20 e 24 hours
after injection) and in a laboratory specifically equipped to
perform leukocyte labelling. Furthermore, the diagnostic
accuracy of WBCS depends on the region of the body in
which the images are performed. The accuracy is somewhat
lower in the central parts of the body than in peripheral
parts (so in case of aortic VGEI) as the tracer is eliminated
via the intestinal tract and physiologically taken up in the
bone marrow, leading to a difficult interpretation of the
aorta. Using antigranulocyte antibody scintigraphy as an
alternative does not demand laboratory labelling, but does
require dual time point imaging and is hampered by phys-
iological uptake in bone marrow and excretion in the in-
testinal tract.40 Moreover, the diagnostic accuracy of
antigranulocyte antibody scintigraphy is, in general, some-
what lower than WBCS.40
The estimated sensitivity of WBCS (without SPECT/CT) in
diagnosing VGEI in the most recent meta-analysis was 0.90
(95% CI 0.85 e 0.94) with a specificity of 0.88 (95% CI 0.81
e 0.94).37 When WBCS was combined with SPECT/CT, the
sensitivity increased to 0.99 (95% CI 0.92 e 1.00), with a
specificity of 0.82 (95% CI 0.57 e 0.96) (Fig. 1).37 It is,
however, not recommended as the first imaging modality in
diagnosing VGEI because of the aforementioned limitations
and limited availability (Fig. 2). VGEI is suspected
g required 18F-FDG-PET/CT
or
WBCS with SPECT/CT
CTA (MRA if CTA is contraindicated)
Limbs
EI) is suspected, divided into thoracic/abdominal and limb grafts.
e angiography; 18F-FDG-PET/CT ¼ 18F-fluoro-D-deoxyglucose posi-
d cell scintigraphy; SPECT/CT ¼ single photon emission computed
information, particularly in inconclusive CT. In some high grade
BCS combined with SPECT/CT may be useful to map the extent of
T/CT can be used.
Recommendation 1
Once vascular graft/endograft infection is suspected,
exhaustive evaluation of clinical status, signs of infection
and patient comorbidities according to the MAGIC criteria
is recommended.
Class Level References
I C Lyons et al. (2016),1 Back
(2014),6 Teebken et al. (2012)12
Recommendation 2
When a vascular graft/endograft infection is suspected, it is
recommended that every effort is made to obtain
microbiological proof of infection.
Class Level References
I C Baron et al. (2013)21
Recommendation 3
To obtain microbiological proof of vascular graft/endograft
infection, the yield of at least three deep rather than
superficial samples should be considered.
Class Level References
IIa C Baron et al. (2013),21 Padberg
et al. (1995)23
Recommendation 4
Microbiological investigation of negative pressure wound
therapy foams should not be performed in order to support
the diagnosis of vascular graft/endograft infection.
Class Level References
III C Scherrer et al. (2016)27
Recommendation 5
Sonification of intra-operatively harvested graft material
may be considered in order to improve the micro-organism
detection rate.
Class Level References
IIb C Wengrowitz et al. (1991)30
Recommendation 6
For patients suspected of vascular graft/endograft infection,
the use of ultrasound as the sole diagnostic modality is not
recommended.
Class Level References
III C Bruggink et al. (2011)34
Recommendation 7
For suspected vascular graft/endograft infection, CTA is
recommended as the first line diagnostic modality.
Class Level References
I B Reinders Folmer et al. (2018)37
Recommendation 8
For patients suspected of vascular graft/endograft infection,
if CTA is contra-indicated, the use of MRAmay be considered.
Class Level References
IIb C Shahidi et al. (2007)38
Recommendation 9
For patients with a clinical suspicion of vascular graft/
endograft infection and with non-convincing findings on
CTA, the use of 18F-FDG-PET combined with low dose CT is
recommended as an additional imaging modality to
improve diagnositc accuracy.
Class Level References
I B Reinders Folmer et al. (2018)37
Recommendation 10
In patients with a clinical suspicion of peripheral vascular
graft/endograft infection, single photon emission computed
tomography, if available, is recommended as an additional
imaging modality to improve diagnostic accuracy.
Class Level References
I B Reinders Folmer et al. (2018)37
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INFECTION
3.1. Raw materials
Currently, vascular devices are mainly made of two
different polymers, PET or expanded polytetrafluoro-
ethylene (ePTFE) for soft materials, and different alloys,
nitinol being the most used, for stents. The choice of
these polymers and alloys is mainly related to their
chemical and mechanical stability, rather than their
properties for inhibiting micro-organism colonisation.
They can be implanted as raw materials or associated
with different adjuncts such as matrices of impregnation
or surface treatment. There is no strong evidence on
differences of susceptibility to infection of synthetic
vascular raw biomaterials. Differences of susceptibility to
infection between PET and ePTFE have been evaluated
in vitro and in vivo with conflicting results. In vivo studies
did not find differences in infectability between PET and
ePTFE materials,46e48 or less adherence of bacteria for
ePTFE than for PET.49 Although all bacteria are able to
adhere to an inert support, some bacteria, such as
coagulase negative staphylococci (e.g., S. epidermidis) or
streptococcus viridans (e.g., Streptococcus mitis oralis),
show a high propensity for adhesion to foreign mate-
rials.50 No significant difference has been found in vivo
between PET and glutaraldehyde treated bovine peri-
cardium, used as aortic patches, to resist bacterial
infection.51 Geometric configuration, early plasma pro-
tein adhesion, and healing sequence can influence the
risk of bacterial adherence with subsequent infection.52
Bacterial strains demonstrated a greater affinity to
352 Nabil Chakfé et al.velour knitted PET than to ePTFE grafts.51 No difference
of susceptibility to infection between different alloys
currently used for stents or stent grafts has been
demonstrated.483.2. Logistics and peri-operative care
3.2.1. Staphylococcus nasal carriage. The high prevalence of
nasal carriage of S. aureus in the general population and its
role in potentially severe VGEIs raises the question of the
beneficial effect of its decolonisation in patients undergoing
vascular surgery.53 In a prospective study, S. aureus nasal
carriage using a PCR technique was not different in patients
with or without post-operative SSIs.54 In another prospec-
tive study, patients undergoing aorto-iliac surgery were
screened for S. aureus nasal carriage and, if positive, were
treated with mupirocin nasal ointment and chlorhexidine
body washes, and compared with a historical control group
of patients who tested positive but received no treatment.
The incidence of S. aureus SSI was significantly lower in
patients who were screened positive and who were treated
for methicillin resistant S. aureus (MRSA) nasal carriage
compared with patients negative for nasal MRSA carriage
(0% vs. 13.6%).55 In addition, both 30 day mortality re-
intervention rates were significantly lower in the treated
group (1.3% vs. 13.6%).55 Of note, S. aureus eradication in
this setting was associated with a decrease in S.aureus
related SSIs but not in the SSIs due to other bacteria, which
may be explained by the competing behaviour of bacteria
causing SSI.55
3.2.2. Peri-operative care
3.2.2.1. Shower regimen and hair removal. In a meta-
analysis, there was no evidence of any benefit from a pre-
operative bathing or shower regimen with antiseptic
agents over unmedicated bathing.56
A number of measures have been found to reduce the
risk of SSI of 51% in patients undergoing open and endo-
vascular elective surgery or elective lower limb amputation:
peri-operative normothermia; hair removal the day before
surgery; and discipline in aseptic care in the operating
room.57
3.2.2.2. Antimicrobial prophylaxis. In a meta-analysis, anti-
microbial prophylaxis with broad spectrum systemic antibi-
otics significantly reduced the risk of wound infection and
early graft infection in arterial reconstructions (relative risk
[RR] 0.25, 95% CI 0.17 e 0.38; and RR 0.31, 95% CI 0.11 e
0.85, respectively).56 In all patients undergoing open or
endovascular abdominal aortic aneurysm repair, therefore
peri-operative systemic antimicrobial prophylaxis is recom-
mended.58 However, antimicrobial prophylaxis for more than
24 hours does not seem to bring any additional benefit.56
Antimicrobial prophylaxis for vascular surgery should
cover the bacteria most likely to be responsible for SSIs and
achieve adequate tissue levels at the time of incision and
throughout the procedure to prevent any bacterialcolonisation of injured skin/soft tissue and implant. First or
second generation cephalosporins are the most widely used
agents owing to their profile of tolerance and antibacterial
spectrum that cover methicillin susceptible staphylococci
(i.e., S. aureus and coagulase negative staphyloccoci),
streptococci, and some Gram negative bacilli. A meta-
analysis of 22 RCTs concluded that prophylactic systemic
antibiotics for patients undergoing peripheral arterial
reconstruction reduced the risk of SSI (RR 0.25, 95% CI 0.17
e 0.38) and early VGI (RR 0.31, 95% CI 0.11 e 0.85).56 In
the same study, no difference in the protective effect on SSI
rate was noted between first or second generation cepha-
losporins, penicillins with lactamase inhibitors, amino-
glycosides, or vancomycin.56
The coverage of MRSA and/or coagulase negative
staphyloccoci may be considered according to the local
prevalence of these strains, even though no significant
difference concerning SSI rates using cefazolin plus vanco-
mycin or daptomycin vs. cefazolin alone has been
found.59,60
Antibiotic prophylaxis has the best efficacy when
administered before the incision (ideally within 30 min)
with re-injection for longer interventions according to the
half life of the compound (i.e., two hours for cefuroxime
and four hours for cefazolin).56
3.2.2.3. Gloves. A prospective RCT did not establish the
benefit of intra-operative glove change before handling
prosthetic grafts.61
3.2.2.4. Wound closure. In a retrospective study including
all SSIs after lower extremity revascularisation procedures
between 2012 and 2016, meticulous wound closure with a
monofilament absorbable suture has been shown to be
superior to staples in decreasing SSI rates.623.3. Antibiotic prophylaxis during dental extraction
Beyond the peri-operative risk of SSI, the implant can be
infected at any time after the intervention, especially in
the presence of bacteraemia (i.e., secondary haematoge-
nous related to SSI). Analogous to prosthetic cardiac
valves, antibiotic prophylaxis after VG for secondary
infection may follow the recommendations of the ESC and
American College of Cardiology/American Heart Associa-
tion.63 In their most recent guidelines, antimicrobial pro-
phylaxis was recommended for patients with a prosthetic
cardiac valve for high risk procedures such as dental pro-
cedures involving the manipulation of the gingival or peri-
apical region of teeth or perforation of the oral mucosa,
including scaling and root canal procedures.63 Antibiotic
prophylaxis has therefore been proposed recently for
those patients with an aortic prosthesis, whether placed
by open surgical repair or endovascular aneurysm repair
(EVAR), before any dental procedure involving the
manipulation of the gingival or peri-apical region of teeth
or perforation of the oral mucosa, including scaling and
root canal procedures.58
Recommendation 11
In every case where a vascular graft/endograft is implanted,
antimicrobial prophylaxis to cover the first 24 hours, by
intravenous administration of a first/second generation
cephalosporin or vancomycin in the event of penicillin
allergy, is recommended.
Class Level References
I A Stewart et al. (2007)56
Recommendation 12
Before implantation of any vascular graft/endograft,
elimination of any potential source of sepsis, especially of
dental origin, should be considered.
Class Level References
IIa C Habib et al. (2015)63
Recommendation 13
Antimicrobial prophylaxis to prevent vascular graft/endograft
infection should be considered before any dental procedure
involving the manipulation of the gingival or peri-apical
region of teeth or perforation of the oral mucosa, including
scaling and root canal procedures for patients previously
operated on with a vascular/endovascular graft.
Class Level References
IIa C Habib et al. (2015)63
ESVS 2020 Management Guidelines for Vascular Graft and Endograft Infections 3534. GENERAL THERAPEUTIC STRATEGIES
In view of the rarity of VGEI, the complexity of diagnosis and
treatment, and the difficulty of the interventions and
severity of complications, centralisation of the patients
suffering from VGEI is clearly indicated. Accordingly, pa-
tients should be transferred to specialised high volume
centres with multidisciplinary experience in VGEI, including
angiologists, vascular, cardiovascular and general surgeons,
microbiologists and radiologists.4.1. Antimicrobial therapy
4.1.1. Choice of antimicrobial therapy. Antimicrobial ther-
apy is an integral part of VGEI treatment. In the acute phase
intensive antimicrobial therapy with broad spectrum anti-
biotics or antibiotics directed against the most likely
infecting organisms is indicated to control infection and
sepsis. In the choice of antimicrobial therapy the fact that
the graft material may be covered with a biofilm and also
the local epidemiology of resistance patterns have to be
considered. In some specific situations, the addition of
antifungal agents should be considered, especially in
visceral fistula cases. Once the responsible infecting or-
ganisms are known the spectrum should be narrowed if
possible.
4.1.2. Duration of treatment. There is no consensus on the
optimal length of antimicrobial therapy for VGEI. Ifprosthetic material can be removed and a thorough
debridement of all infected tissue can be performed, a
minimum of two weeks of intravenous therapy, if
possible, followed by an oral regimen for another two to
four weeks is indicated. If the infected material is
replaced by a new VG, four to six weeks of intensive
antimicrobial therapy is usually proposed to prevent
recurrent infection. Many authors favour a total treat-
ment time of three to six months in this situation, and
some even advocate one year of treatment. In those
patients in whom general conditions preclude any sur-
gery, lifelong treatment should be considered.64,65 This
can be an option in patients at higher risk of surgery,
especially in low grade infections with less virulent
infecting organisms, susceptible to suitable antibiotics,
and without other complications. In some cases, the
infection cannot be totally eradicated but kept under
control by year long or even lifelong therapy.66
4.1.3. Antimicrobial therapy management. Because of the
complexity of interpreting microbiological tests results and
the permanent evolution of antimicrobial therapies and
micro-organism resistance, antimicrobial therapy manage-
ment must be done by an infectious diseases specialist
within a multidisciplinary team, including vascular surgeons,
radiologists, microbiologists, anaesthetists, and gastroin-
testinal and pulmonary specialists for cases with a
concomitant fistula.65,67
4.1.4. Isolation. Patients with multidrug resistant (MDR)
bacteria (such as MRSA, but not methicillin resistant
coagulase negative staphylococci, extended spectrum
beta lactamase producing Enterobacteriaceae, or glyco-
peptide resistant enterococi) should be isolated and
should remain isolated during the hospital stay as carriage
is prolonged, especially in patients receiving antibiotics.
The wearing of gloves is required for the manipulation of
any biological material, but this is not specific to MDR
bacteria (gown for any contact with the patient, mask if
pulmonary colonisation or infection). Both colonised and
infected patients with these bacteria should be managed
in a single patient room to reduce the risk of spread to
other patients.684.2. Surgical principles
Historically, total removal of the infected VG or EG,
debridement and rinsing with antiseptic solution of the
infected area, and extra-anatomic reconstruction (EAR)
outside the infected field was considered as the gold
standard to avoid recurrent infection. This procedure
should be performed in two stages when possible. How-
ever, this approach is not always feasible, often not easy,
and increases the risk of complications like stump
blowout. Therefore, most authors now prefer an in situ
reconstruction (ISR) with infection resistant material
combined with removal of the infected graft material,
aggressive debridement of the arterial bed and targeted
antimicrobial therapy.67,69 In most situations the
354 Nabil Chakfé et al.results with ISR are at least equivalent to extra-anatomic
repair.
In thoracic and abdominal procedures especially, it is
recommended that any VG and anastomosis should
be covered with viable tissue such as omentum, muscle,
or pericardial patch.70 Direct contact with viscera or
organs should also be avoided. If no viable tissue is
available, a bovine pericardial patch can be used. Anas-
tomoses or suture lines can be reinforced with fascia or
pledgets.Recommendation 14
Antimicrobial therapy is recommended in every patient with
an infected graft/endograft.
Class Level References
I B Darouiche (2004),65 Revest
et al. (2015)67
Recommendation 15
For the diagnosis and treatment of vascular graft/endograft
infection it is recommended that the patient be transferred
to specialised high volume centre with multidisciplinary
experience in this pathology.
Class Level References
I C Consensus of expert opinion5. SUPRA-AORTIC TRUNKS
5.1. Specific aspects
5.1.1. Incidence. The exact incidence of VGEI in the supra-
aortic trunks (SAT) is unknown, but probably extremely
low. SAT VGEI includes prosthetic patch, bypass, and stent
graft infections.71 However, infection rates might be
underestimated, owing to lack of recognition and under
reporting, as in other locations.
Over the last three decades, a total of 140 cases of SAT
patch/bypass infections have been reported, mostly
involving carotid patches. An overall incidence of 0.25% e
0.5% was reported in a systematic review of carotid end-
arterectomies involving PET patches.72 Because of its
infrequent occurrence, it is difficult to identify the aetiology
of SAT EG or endograft infection (EGI), but haematoma
could be a risk factor in promoting the development of early
infection.73,74
The incidence of SAT EGI is low, with an estimated
incidence of less than one EGI in 10 000 cases.75 A sys-
tematic review of the literature identified only 12 patients
with SAT stent graft infections in the last three decades:
eight patients presented with infected carotid stent graft,
three with infected subclavian stent graft, and one with an
infected tandem brachiocephalic and subclavian artery
stent graft.715.1.2. Clinical presentation. Half of all reported infections
occurred within the first four post-operative months and
involved carotid patches. The most common clinical
presentation for early infection is abscess, neck mass,
and haemorrhage. When infection presents later, the
main symptom is a draining sinus. Patients with SAT
stent graft infection typically present with fever, malaise,
and pain. SAT stent graft infection is mostly encountered
after stent graft implantation for carotid blowout syn-
drome.76,77 However, it is often a diagnosis of exclusion
after other sources of bacteraemia are excluded or
inconclusive.72,74,78 In the setting of early post-operative
infection, S. aureus is the most commonly encountered
micro-organism, while S. epidermidis is the predominant
pathogen in patients who present with late
infections.71,79
5.1.3. Specific diagnostic modalities. US allows the evalu-
ation of the patency of the revascularisation, the presence
of a collection, and its characterisation. It has been high-
lighted that carotid patch corrugation on US might be an
early warning sign of VGI.80 CTA in combination with ce-
rebral CT may show pseudo-aneurysm formation, abscess,
thrombosis or perivascular stranding, and brain abscesses.815.2. Treatment options for supra-aortic trunk vascular
graft/endograft infection
5.2.1. Conservative treatment. Conservative treatment of
SAT VGEI is not recommended in patients fit for interven-
tion because of the risk of suture line rupture for patch/
bypass and vascular wall necrosis for stent graft, potentially
leading to uncontrollable major bleeding in the chest and
tracheal compression in the neck. However, successful
conservative treatment of the infected stent graft using
parenteral antimicrobial therapy alone has been
described.75
5.2.2. Endovascular treatment. Endovascular treatment is
also an option for SAT VGEI. It is mostly used in life
threatening presentations in order to control a major
bleeding related to VGEI.82 For acute bleeding related to
blowout syndrome, open surgery in an irradiated area may
be challenging, and emergency operative ligation may be
associated with high rates of major morbidity, meaning
that an endovascular approach is usually preferred. A
systematic review and meta-analysis including 559 pa-
tients demonstrated that both coil embolisation and
reconstruction with stent grafts may be safe treatment
options for carotid blowout syndrome: peri-operative
mortality was 3% for patients treated by carotid emboli-
sation and 12% for patients treated with covered stent
grafts, while the peri-operative stroke rate was 1% in both
groups.83
The stent graft first strategy can also be considered as a
bridge to definitive therapy in unstable patients. This
Open surgery Management
Described cases
n = 140
Described treatment
n = 138
Removal of infected material +
arterial reconstruction
n = 86
Phlegmon excision (n = 2)
EndoVAC (n = 10)
Ligation (n = 7)
Covered stent (n = 7)
(Including 1 muscle flap)
Conservative treatment (n = 26)
Veins (n = 71) (1 muscle flap)
SFA (n = 7) (4 muscle flaps)
Prosthetic grafts (n =4)
Arterial homografts (n = 3)
Primary closure + flap (n = 1)
Outcomes
None (n = 41), nerve injury (n = 15), stroke (n = 8),
re-infection (n =4), bleeding (n = 3),
cardiac failure (n = 2), missing data (n = 2)
None (n = 5), nerve injury (n = 1), re-infection (n = 1)
None (n = 3), stroke (n = 1)
None (n = 3)
None (n = 1)
None (n = 2)
None (n = 10)
None (n = 6), nerve injury (n = 1)
None (n = 21), cardiac failure (n = 1)
None (n = 3), bleeding (n = 1)
Figure 3. Management and outcomes of supra-aortic trunk patch/bypass infection.71 SFA ¼ superficial femoral artery; VAC ¼ vacuum
assisted closure.
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including excision and reconstruction. Patients should
receive intravenous broad spectrum or microbiology based
antimicrobial therapy, followed by long term treatment.
The endo vacuum assisted closure (VAC) technique is a
hybrid approach that has been used in 10 cases of infected
SAT reconstructions. The EndoVAC technique is a three step
procedure: relining of the infected reconstruction with a stent
graft; removal of the infected VG without clamping; and use
of NPWT to permit granulation.84,85 This technique provided
good results but was performed in few patients selected on
an individual basis for the treatment as they had severe co-
morbidity and adverse anatomy, providing limited evidence.
5.2.3. Reconstruction
5.2.3.1. Graft material. A surgical approach with total
explantation of infected foreign material is recommended in
the elective setting only. Replacement of the explanted
bypass/patch or arterial segment is usually mandatory
to avoid cerebral ischaemia or infarction. However, primary
ligation of the vessel may be considered in emergency life
threatening situations, if the infected reconstruction is
already thrombosed without neurological symptoms or with
an already completed cerebral infarct, to avoid revascular-
isation syndrome and cerebral haemorrhage.86
Autologous material is usually considered as the first line
option for reconstruction. Because of the typically short length
of these reconstructions, autologous saphenous vein recon-
struction (bypass or patch) can be performed in the majority
of cases.79,87,88
5.2.3.2. Partial or total explantation. A direct surgical
approach with total explantation of the foreign material is
mostly performed in non-emergency conditions in anattempt to avoid emergency procedures for life threatening
haemorrhage in the neck or chest. Usually, bypasses and
arterial segments with infected patches or stent grafts are
short, except bypasses starting from the ascending aorta.89
Consequently total explantation is usually performed.
Obtaining proximal arterial control is mandatory, even
using an occlusion balloon or at an unscarred site through
a sternotomy or a thoracotomy, in order safely to enter
the cervical phlegmon and minimise peri-operative
complications.90
The approach that involves proximal arterial control is
even more relevant in cases with active bleeding due to
infection associated arterial wall breakdown.90e92 Indeed,
primary arterial control through the same cervical incision
may be difficult, with the risk of significant blood loss and
increased inadvertent peripheral nerve injuries.
Partial explantation with local wound debridement is less
often performed.
5.2.3.3. Adjunctive therapy. A muscle flap may be consid-
ered as a possible adjunctive option for SAT VGEI infection.
Sternocleidomastoid or pectoralis major muscle flaps have
been reported in 11 cases following SAT patch/bypass in-
fections. Of these 11, seven flaps were following complete
removal of the infected material and arterial reconstruction,
while four flaps were combined with local wound
debridement.93e96 None of the 11 patients died from a
related cause. Of the seven patients who underwent com-
plete removal of the infected material and arterial recon-
struction, one stroke and two transient nerve injuries were
reported. Of the four patients who underwent local wound
debridement, one pseudo-aneurysm occurred requiring the
placement of a covered stent.
Recommendation 20
Conservative treatment, including antimicrobial therapy
without reconstruction, for supra-aortic trunk vascular
graft/endograft infection may be considered for patients
unfit for surgery.
Class Level References
IIb C Myles et al. (2000)75
356 Nabil Chakfé et al.5.3. Follow up and prognosis
Over the last three decades, 140 cases of SAT patch/bypass
infections have been reported and 138 treatment modalities
described: total removal of infected material and arterial
reconstruction in 86 cases; phlegmon excision in two cases;
the EndoVAC technique in 10; ligation in seven; endovascular
treatment using covered stent grafts in seven; and conser-
vative treatment in 26 cases.71 Peri-operative complications
occurred in 27.9% of cases. Six patients died from related
causes with a median follow up of 36 months (Fig. 3).71
Of the 12 cases of SAT stent graft infections reported over
the last three decades, 11 treatment modalities were
described: stent graft removal and arterial reconstruction in
six cases; stent graft removal without arterial reconstruction
in two cases; carotid embolisation in two cases; and con-
servative treatment in one case. Peri-operative complica-
tions were described in 54.6% of cases. Median follow up
was 4.5 months, and five patients died from related causes
(Fig. 4).71Recommendation 18
The EndoVAC technique may be considered as a treatment
option in selected patients with supra-aortic trunk vascular
graft/endograft infection when neither total removal of
infected material nor when usual conservative VAC therapy
are considered feasible or safe.
Class Level References
IIb C Kragsterman et al. (2011),84
Thorbjornsen et al. (2016)85
Recommendation 19
In the emergency setting with active bleeding in patients
with supra-aortic trunk vascular graft/endograft infection,
a combined endovascular and surgical approach may be
considered.
Class Level References
IIb C Younis et al. (2006)82
Recommendation 16
When patch corrugation is found on ultrasound follow up
after carotid endarterectomy further investigations may be
considered to exclude a vascular graft infection.
Class Level References
IIb C Lazaris et al. (2005)80
Recommendation 17
For patients with supra-aortic trunk vascular graft/endograft
infection, total removal of infected material followed by
reconstruction with autologous material is recommended.
Class Level References
I C Lejay et al. (2018),71 Son et al.
(2014),79 Grazziotin et al.
(2002),87 Kaviani et al. (2006)886. THORACIC/THORACO-ABDOMINAL AORTA
6.1. Specific aspects
6.1.1. Incidence. The frequency of thoracic aortic VGEI
is reported to be up to 6%, with mortality rates, depending
on the clinical presentation, of up to 75%.15,64 Together
with the increasing number of procedures performed on
the thoracic aorta, including thoracic EVAR (TEVAR), the
incidence of thoracic VGEI is also increasing. Additionally,
thoracic VGEI is often associated with AEsF, ABF, or aorto-
pulmonary fistula (APF), which makes treatment more
complicated, with the need (besides the aortic reconstruc-
tion) for adjunctive surgical procedures to repair the oeso-
phageal or bronchial lesion.97e99
A systematic review identified 43 studies reporting on
233 patients with 49 VGI and 184 EGI. Only four were
multicentre studies, which included 107 patients, all with
EGI. The remaining 39 single centre studies included 49
patients with VGI and 77 with EGI.100 In two large registries
on complications after TEVAR, the incidence of AEsF was
estimated to be 1.7% and 1.5%, respectively.97,99 In a sys-
tematic review, the association with AEF was significantly
more frequent (60% vs. 31%) and the time interval from
index procedure to infection was significantly shorter (17 
21 months vs. 32  61 months) with EG compared with VG,
respectively.100
6.1.2. Clinical presentation. The clinical symptoms of
thoracic aortic VGEI can range from unexplained fever, as
observed in post-implantation syndrome, to sepsis, massive
bleeding, and shock. Owing to the depth of the thoracic
aorta, visible local signs of infection are mostly absent.
Septic emboli can cause secondary loci of infection or even
abscesses. For AEsF or ABF, haematemesis or haemoptysis
may be the first symptom. This bleeding may be massive,
especially for AEsF but is often preceded by self limiting
“herald bleeding”.
6.1.3. Specific diagnostic modalities. Definite diagnosis
mostly demands a CTA showing perigraft fluid, air in the
aneurysm sac or surrounding it, or abscess formation in the
surrounding tissues.1,8 18F-FDG-PET/CT should be per-
formed when low grade infection is suspected but not
confirmed by CT.43 When an AEsF is present, the prosthetic
material may be seen protruding in the oesophagus on
oesophagoscopy. In case of an ABF the defect in the
bronchus can only be seen when it is centrally located, e.g.,
in the left main bronchus. Diagnostic examinations should
Endovascular surgery Management Outcomes
Described cases
n = 12
Described treatment
n = 11
Stent removal + arterial reconstruction with venous substitutes
n = 6
Stent removal without arterial reconstruction
n = 2
Carotid embolisation
n = 2
Conservative treatment
n = 1
None (n = 3), death (n = 1), cardiac failure (n = 1),
re-infection (n = 1)
Stroke (n = 2)
None (n = 1), bleeding (n = 1)
None (n = 1)
Figure 4. Management and outcomes of supra-aortic trunk SAT stent graft infection.71
ESVS 2020 Management Guidelines for Vascular Graft and Endograft Infections 357be performed without delay when infection of a thoracic
aortic VGEI is suspected.666.2. Thoracic vascular graft/endograft infection without
fistula
6.2.1. Conservative treatment. Although surgical princi-
ples dictate control of sepsis, removal of all infected
prosthetic material, and reconstruction in a clean field,
this is not always achievable because it places a huge
burden on an already sick patient (Fig. 5). Therefore,No fistula
Thoracic aortic VGEI
Acute bleeding
Yes
No
Conservative or palliative
treatment
Antibiotics
Drainage
Irrigation
Consider bridge treatment
with endograft
Fit for
Vascular reconstruction
In situ 1st choice†
Extra-anatomical
Graft explantation
Total if possible
Partial if well incorporated
C
*
*
*
Figure 5. Proposed algorithm for the management of thoracic aortic gra
that can be used are cryoprerved allografts, treated PET grafts or biolo
polyethylene terephthalate.staged repair or conservative treatment are the only
options.101
6.2.1.1. Percutaneous drainage. In the presence of peri-
graft fluid collections or abscesses, percutaneous drainage
under ultrasound or CT guidance can be performed in
combination with antimicrobial therapy. A 10 e 14 F pigtail
catheter or a 12 e 20 F drain is inserted percutaneously
and left in place until the collection is totally or sufficiently
drained.
6.2.1.2. Irrigation. Irrigation with saline or an antiseptic
solution can be used in order to dilute the bacterial burdenAirway fistula
Yes
No
 surgery
Prolonged antibiotics
Long-term follow-up
Consider endograft if
Limited signs of infection
High operative risk of resection
Oesophageal fistula
losure of oesophagus
Suture if small fistula
Oesophagectomy
Closure of airway defect
Brochial suture
Pulmonary resection
ft/endograft infection. * In a single or staged prodecure. y Materials
gical xenografts. VGEI ¼ vascular graft/endograft infection; PET ¼
358 Nabil Chakfé et al.in prosthetic and peri-prosthetic tissues. It can be per-
formed through percutaneous drains or after a surgical
procedure with aortic reconstruction.66
In a systematic review of single centre series, conser-
vative treatment (antimicrobial therapy with or without
percutaneously inserted drainage of fluid collections or
flushing) was performed in 2% of patients with VGI (n ¼
1/49) and 17% with EGI (n ¼ 13/77). The mortality rate
was 100% at 30 days in VGI group; and 38% at 30 days,
75% at one year, and 100% at five years in the EGI
group.100
Five studies provided data on one year mortality in both
conservatively (n ¼ 12) and surgically (n ¼ 42) treated
patients.102e106 One year mortality was 75% and 50%,
respectively, without any significant difference.100
6.2.2. In situ reconstruction. Removal of the infected graft
material, aggressive debridement of the arterial bed, and
arterial reconstruction with suturing in healthy non-infected
tissue using infection resistant material constitute the basis
of this treatment modality
6.2.2.1. Specific techniques. The operative technique
largely depends on the VG or EG location. If the pros-
thesis extends into the aortic arch, a median sternotomy
or a clamshell incision is indicated, and the intervention
needs to be performed under total cardiopulmonary
bypass, circulatory arrest, and selective cerebral perfu-
sion. If the proximal extent of the VG or EG is distal to the
left subclavian artery (LSCA), the procedure can be per-
formed through a left thoracotomy with single lung
ventilation and left heart bypass. Dissection of the prox-
imal neck, usually between the left common carotid ar-
tery (LCCA) and the LSCA, can be difficult owing to the
inflammation caused by the infection or the previous
intervention. Care should be taken not to damage adja-
cent structures, like the lung, vagus nerve, or oesophagus.
If extensive reconstructions need to be performed, mea-
sures like cerebrospinal fluid drainage may be considered
in order to reduce the risk of spinal cord ischaemia. Intra-
operative evaluation using motor evoked or somatosen-
sory evoked potentials may also be used. If the VG or EG
extends to the level of the LSCA and clamping between
the LCCA and the LSCA is not possible, hypothermic cir-
culatory arrest is needed to allow complete prosthetic
material excision.107 When exposure of the thoraco-
abdominal aorta is required, a thoracophrenolaparotomy
is the preferred approach. As in primary procedures, the
splanchnic arteries can be perfused with normothermic
blood and the renal arteries with cold crystalloids during
cross clamping.
6.2.2.2. Graft materials. Cryopreserved aortic allografts
have been proposed for the replacement of infected
thoracic VGEI.102,108 As a biological material, allografts have
demonstrated a higher resistance to infection than syn-
thetic VGs, but are exposed to the subsequent risk of
degeneration, rupture, and bleeding when the infection is
caused by necrotising organisms, such as P. aeruginosa or
Candida spp.66,109e111 Long term durability results,especially with regard to the development of calcification
and aneurysms when used in the thoracic aorta, are still
lacking.64
Treated PET VGs, such as rifampicin soaked and silver
coated (with or without triclosan) VGs, have been pro-
posed in order to decrease the risk of early infec-
tion.64,66,112 In a series including mainly explanted
infected abdominal endografts, treated PET VGs have been
shown to provide better results in terms of prevention of
re-infection and five year overall survival than standard
PET VGs (53% vs. 12%) These results can probably be
extrapolated to the TEVAR setting. Bovine pericardium has
been reported as a technical option for ISR of thoracic
aortic VGEI, tailoring a custom made tube by sewing
pericardial sheets.113e115 While promoted in case series,
this technique still needs further studies and longer follow
up.
6.2.2.3. Adjunctive therapy. The recommended VG
coverage to avoid its direct contact with surrounding or-
gans like lung or oesophagus using the surrounding tissues
is often not possible. Therefore, it is advised to cover the
VG with other viable tissue. Intercostal flap coverage can be
used, as well as pericardial or omental flaps. An intercostal
flap has limited volume and is best prepared at the
moment of thoracotomy to avoid damage caused by the
retractor. When a pericardial flap is used, the pericardial
defect may need to be repaired with synthetic material.
Omentum can be prepared by laparoscopic access and
routed through the diaphragm via the aortic hiatus, to
cover the VG and fill a dead space after mediastinal
debridement.66 More extensive muscular flaps, such as la-
tissimus dorsi or serratus muscle have been proposed.101 If
there is no viable tissue available, use of a bovine peri-
cardial patch is suggested.
6.2.3. Extra-anatomic reconstruction. To avoid reconstruc-
tion in a contaminated field and recurrent infection, EAR
outside the infected field and secondary aortic ligation with
removal of the infected VG or EG can be performed in one
or two stages.
6.2.3.1. Technique. To restore distal perfusion after aortic
ligation, axillo-bifemoral or bilateral axillofemoral bypasses
can be performed, but retrograde blood flow to the visceral
organs under all these circumstances may be insufficient.101
The most commonly used EAR is the so called ventral aorta,
consisting of a retrosternally placed VG that originates
from the ascending aorta, the distal anastomosis being
on the supracoeliac abdominal aorta or more distally, on
the infrarenal aorta or iliac arteries.101,116 If possible, this
reconstruction is performed in two steps, the first step
being the bypass through sternotomy and upper laparot-
omy, and the second step being the removal of the thoracic
VG or EG through thoracotomy.66 The main limitations of
this technique are acute bleeding, or involvement of the
aortic arch because of the necessity to intervene first on the
infected VG or EG.100 Depending on the situation, alterna-
tive routes can be used, such as a posterior pericardial
bypass.
Recommendation 25
For patients with suspected thoracic graft/endograft
infection, in the absence of fistulisation to the oesophagus
or airway, or generalised sepsis, prolonged antimicrobial
therapy combined with drainage of peri-graft fluid and/or
irrigation, may be considered.
Class Level References
IIb C Kahlberg et al. (2019)100
Recommendation 26
For patients with thoracic/thoraco-abdominal vascular graft/
endograft infection, partial explantation may be considered if
infection is limited.
Class Level References
IIb C Kahlberg et al. (2019)100
Recommendation 27
For the reconstruction of thoracic/thoraco-abdominal
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and covered with an omental or muscular flap in order to
reinforce the stump and diminish the risk of blow out.101
Typically, the aorta is transected just distal to the LSCA
origin or at the level of the diaphragm. Alternatively, sta-
plers can be used to divide the aorta, but these stapled
stumps should also be covered with viable tissue, such as
pedicled intercostal muscle flap.101
6.2.4. Partial or total graft explantation. Partial removal of
graft material is usually not an option as the whole of the VG or
EG needs to be considered to be infected,109 the only exception
being when only part of the VG or EG is documented as being
infected through clinical and imaging findings.109
In a meta-analysis, the one year mortality was 37% (n¼ 15/
41) for graft material explantation vs. 85% (n¼ 17/20) for total
or partial graft material preservation.100 In a systematic review
and meta-analysis including 96 patients with infected thoracic
endografts (41 EG explantation, 55 EG preservation), in hospital
mortality was 37% vs. 42%, while late mortality was 46% vs.
82% for EG explantation and EG preservation, respectively.117Recommendation 21
For persistent fever or inflammatory symptoms after
implantation of a thoracic graft/endograft, further
diagnostic investigations are recommended in the search
for infection.
Class Level References
I C Lyons et al. (2016)1
Recommendation 22
For fit patients with proven thoracic/thoraco-abdominal
vascular graft/endograft infection, total graft explantation
is recommended.
Class Level References
I B Kahlberg et al. (2019),100
Moulakakis et al. (2013)117
Recommendation 23
For patients with in situ reconstructions of thoracic/thoraco-
abdominal vascular graft/endograft infection, coverage of
the newly inserted graft with autologous, and ideally
vascularised, tissue is recommended.
Class Level References
I C Spiliotopoulos et al. (2018),66
Roselli et al. (2014)101
Recommendation 24
For patients with thoracic vascular graft/endograft infection
that are at major risk of surgery, conservative treatment may
be considered.
Class Level References
IIb B Czerny et al. (2014),97 Kahlberg
et al. (2019),100 Chiesa et al.
(2010)111
vascular graft/endograft infection, cryopreserved allografts
may be considered the first choice graft material.
Class Level References
IIb C Smeds et al. (2016)110
Recommendation 28
After extra-anatomic reconstruction for thoracic/thoraco-
abdominal vascular graft/endograft infection, reinforcement
of the aortic stump with autologous, and ideally
vascularised, tissues should be considered.
Class Level References
IIa C Roselli et al. (2014)1016.3. Thoracic vascular graft or endograft infection with
oesophageal fistula
Thoracic aortic VGEIs associated with AEsF or ABF require a
more complex and difficult treatment than those without the
presence of a fistula. Even when an aortic VG is resected and
the oesophagus repaired, the mortality is twice that of a
VGEI without fistula.117 An AEsF seems to occur more
frequently and earlier in the thoracic aorta than in the
abdominal aorta and after EG than VG implantation.110
Any strategy in this patient population needs to be highly
individualised given the risks associated with major thoracic
aortic surgery often in a hostile operative field.
6.3.1. Conservative treatment. Conservative treatment of
an AEsF is almost invariably fatal.97,99,103,110 Only one
conservatively managed case of secondary AEsF after EG
implantation without sign of recurrent haemorrhage or
chronic mediastinitis at 14 months has been described.118
Conservative treatment should be considered palliative in
patients unfit for major surgery.
6.3.2. Endovascular treatment as bridging therapy. In pa-
tients presenting active and life threatening bleeding from
360 Nabil Chakfé et al.an AEsF, emergency EG insertion may be proposed as the
primary strategy to control bleeding and restore haemo-
dynamic stability.119 This approach has been proposed as a
“stopgap” strategy. However, it has considerable limitations,
mainly related to the inability to eliminate the primary
infected material and therefore should be considered
mainly as a bridge to definitive treatment.64
In a national survey that analysed 25 cases of AEsF and
ABF treated by TEVAR, the 30 day mortality rate was 28%.
After a follow up of 23 months, overall mortality was 44%
and the re-intervention rate due to TEVAR failure was 28%,
with an associated re-intervention mortality rate of 60%.
Patients treated by TEVAR associated with oesophageal or
bronchial repair had a lower mortality than patients treated
with TEVAR alone (30% vs. 55%).99 The European Registry of
Endovascular Aortic Repair Complications (EuREC) also
showed a statistically significant survival benefit for a radical
surgical approach compared with any other treatment
strategy in cases of AEsF after TEVAR.97 Other reports
confirmed the idea that patients with VGEI, treated by
initial TEVAR and considered unfit for subsequent definitive
open surgical repair, had the worst prognosis, with mortality
approaching 100% in most series.64
To conclude, patients with bleeding due to an AEsF can
be treated successfully in the emergency setting by TEVAR,
but once they have recovered and conditions are stable, a
definitive surgical procedure must be performed to ensure
durable results.100,106
6.3.3. Treatment of the oesophagus
6.3.3.1. Limited treatment of fistula. In the presence of an
AEsF, both the aortic and oesophageal lesions need to be
addressed. To avoid persistent or recurrent infection and/or
mediastinitis and fistula recurrence, closure of the oeso-
phageal lesion is needed. This can be performed together
with the vascular reconstruction or as an isolated
procedure.
Administration of methylene blue through a naso-
oesophageal tube can help to localise a small oesophageal
lesion. If the lesion is limited, primary oesophageal repair
can be accomplished by a double layer of absorbable
interrupted stitches to the oesophageal wall. In this case,
the oesophageal repair is usually reinforced and covered by
a pericardial flap or a previously prepared pedicled inter-
costal muscle flap.64 Primary repair of the oesophageal
defect always entails the risk of anastomotic leakage and
mediastinitis with the subsequent need to remove the
oesophagus. Therefore, most authors agree that limited
fistula treatment has a limited place in treatment of
AEsF.112
6.3.3.2. Radical fistula treatment. In most cases, the
oesophageal lesion cannot be repaired primarily because it
is too large, the oesophageal wall is of insufficient quality or
ischaemic, or the infection is too extensive. In these situa-
tions, more radical treatment with partial or total resection
of the oesophagus is indicated. When a staged procedure is
used, in a first step (e.g., when a thoracic EG is inserted to
control the bleeding) a cervicostomy with closure of thecervical oesophagus and a nutritional gastro- or jejunos-
tomy is performed. This is followed by removal of the
oesophagus and reconstruction with gastric or colonic pull
up in a second or third stage.100
6.3.3.3. Oesophageal prosthesis. The goal of the oesopha-
geal endoprosthesis implantation is to close the fistula from
the oesophageal side and prevent further contamination of
the mediastinum. It can be performed as a standalone
procedure or be combined with aortic stenting in the case
of bleeding.120 In a EuREC report, survival at one year was
only 17% with oesophageal stenting alone vs. 43% when
oesophagectomy was performed.97 Therefore, this tech-
nique should only be considered in patients unfit for further
surgery. Migration of the stent with need for repositioning
can occur.121
6.3.3.4. Definitive treatment: one or two stage. When
massive bleeding occurs, insertion of an EG to control the
bleeding can be a life saving procedure. Multiple combi-
nations of treatment options have been used to deal with
AEsF, including arterial ISR, extra-anatomic bypass with
concomitant primary oesophageal repair, or oesophagec-
tomy with cervical oesophagostomy and secondary resto-
ration of gastrointestinal tract continuity.109,112
Resection of the oesophagus and restoration of gastro-
intestinal continuity can be performed in a one stage or two
stage procedure. The same applies to the vascular recon-
struction and resection of the aortic graft.105 The choice of
strategy to be followed will often depend on the urgency of
the situation, the condition of the patient and the possi-
bility of controlling the infection.
Encouraging results were reported in a series of eight
patients operated on for AEsF or ABF by means of a staged
approach: emergency endovascular exclusion of the aortic
rupture, followed by staged open surgical repair of the
oesophageal or bronchial lesion and removal of the infected
aortic graft with associated intercostal muscle flap inter-
position. At a mean follow up of 34 months, one death was
observed (87.5% overall survival), and no conversion or
aortic bleeding was recorded.122
In every case, patients should receive intensive medical
and nutritional support to get them into a better general
condition before being referred for open surgery.1236.4. Thoracic vascular graft or endograft infection with
airway fistula
In the EuREC registry, the incidence of ABF and APF is
0.56%.98
6.4.1. Endovascular treatment. Acceptable results have
been described after treatment of ABF or APF by TEVAR,
with the risk of delayed recurrent fistula or persistent
infection, despite EG coverage with a muscle or pleural
flap.124,125 In the EuREC report, 15 patients presented with
ABF, predominantly on the left side (n ¼ 14/15) and 11 with
APF of 4 680 TEVAR procedures. In half of the patients,
external compression, mostly due to presence of an endo-
leak, was considered to be the responsible mechanism.
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emergency TEVAR for ABF can be performed with 93.2%
technical success in the short term, and 5.9% 30 day mor-
tality.126 Aortic related mortality was 14.3% at 17.4 months,
and ABF recurrence was 11.1%.126 Despite these results, the
risk of ABF recurrence and infection of the newly inserted
EG remains, as the defect in the respiratory system is not
treated.119
In a systematic review with meta-analysis of patients that
underwent TEVAR for AEsF or ABF, 114 patients were
included (71 ABF and 43 AEsF). Patients with AEsF pre-
sented more frequently with hypovolaemic shock (33% vs.
13%) and systemic infection (36% vs. 9%) than patients with
ABF. In hospital mortality was 3% for ABF and 19% for AEsF.
Additional procedures after TEVAR and within the first 30
days were performed in 3% of ABF and 37% of patients with
AEsF. Therefore, ABF and AEsF are not comparable and
should be considered separately.127
6.4.2. Open surgical treatment. Open ABF operative mor-
tality ranged from 15% to 41%.123,128 Open surgical treat-
ment remains the first choice for patients fit for surgery as
the EuREC registry showed that a radical surgical approach
resulted in significantly better survival (63% at two years)
compared with any other treatment strategy.98
To decrease the risk of ABF recurrence and re-infection,
the bronchial defect needs to be repaired surgically. The
defect can be closed primarily or with an intercostal muscle
or pericardial flap, but in most cases a bronchial resection
and anastomosis or a lung resection (mostly wedge resec-
tion) is necessary. After bronchus repair, the EG should be
covered with a muscle or pleural flap.99,123 Sometimes APF
can be treated successfully in a more conservative manner
by implantation of an EG to control the bleeding, followed
by conservative treatment with antimicrobial agents. For
persistent infection or recurrent of EG infection, pulmonary
resection is indicated.123
It is not clear whether the EG always needs to be
removed to definitely treat an ABF.129 In patients fit for
surgery, EG removal and in situ vascular repair should be
considered.125,126,1306.5. Follow up and prognosis
Overall mid term mortality ranges from 14.3% to 75% but
largely depends on presentation, the condition of the pa-
tient, and the treatment that has been given.64,66,99,105,126
The presence of an AEsF or ABF is a worsening prognostic
factor.
Follow up, including inflammatory parameter monitoring
and repeated imaging with CTA and/or 18F-FDG-PET/CT,
remains indicated for a longer time to detect delayed
recurrent infection and the risk of degeneration of cry-
opreserved allograft when used.
Recurrence or persistent infection and subsequent multi-
organ failure due to septic shock are the main reasons for
the demise of these patients.66 Secondary interventionsdue to infective or bleeding complications can be needed in
up to 50% of patients.105
Recommendation 29
For patients with aorto-oesophageal fistula complicating
thoracic/thoraco-abdominal vascular graft/endograft
infection, explantation of the infected material, repair of
the oesophagus, and coverage with viable tissue is
recommended as definitive treatment.Class Level ReferencesI B Kahlberg et al. (2019),100
Moulakakis et al. (2013)117Recommendation 30
In the emergency setting with active bleeding complicating
thoracic/thoraco-abdominal vascular graft/endograft
infection with an aorto-oesophageal fistula, initial
treatment with an aortic endograft, as a bridge to definitive
treatment, should be considered.Class Level ReferencesIIa B Chiesa et al. (2010),99 Chiesa et
al. (2010),111 Canaud et al.
(2014),125 Canaud et al.
(2014)130Recommendation 31
Conservative treatment of patients with an aorto-
oesophageal fistula complicating thoracic/thoraco-
abdominal vascular graft/endograft infection is not
recommended, except in a palliative setting.Class Level ReferencesIII B Czerny et al. (2014),97 Chiesa et
al. (2010),99 Smeds et al.
(2016),110 Chiesa et al.
(2010)111Recommendation 32
Treatment of aorto-oesophageal fistula complicating
thoracic/thoraco-abdominal vascular graft/endograft
infection with an oesophageal endoprosthesis alone is not
recommended.Class Level ReferencesIII C Czerny et al. (2014)97Recommendation 33
In patients with aortobronchial or aortopulmonary fistula
complicating thoracic/thoraco-abdominal vascular graft/
endograft infection, closure of the airway defect and
explantation of the infected material with in situ
reconstruction should be considered as definitive treatment.Class Level ReferencesIIa C Czerny et al. (2015),98 Chiesa et
al. (2010),99 Chiesa et al.
(2010)111
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In the emergency setting of active bleeding complicating
thoracic/thoraco-abdominal vascular graft/endograft
infection with an aortobronchial or aortopulmonary fistula,
treatment with an aortic endograft should be considered.Class Level ReferencesIIa C Canaud et al. (2013),123 Canaud
et al. (2013)126Recommendation 35
For patients with an aortobronchial or aortopulmonary
fistula complicating thoracic/thoraco-abdominal vascular
graft/endograft infection, preservation of the endograft
may be considered after closure of the airway defect and
coverage with viable tissue.Class Level ReferencesIIa C Canaud et al. (2013),123 Canaud
et al. (2013)126Recommendation 36
For all patients treated for thoracic/thoraco-abdominal
vascular graft/endograft infection, lifelong follow up is
recommended because of the risk of recurrent infections or
fistulae.Class Level ReferencesI C Kahlberg et al. (2017),64
Spiliotopoulos et al. (2018),66
Kahlberg et al. (2019),100 Luehr
et al. (2014)1057. ABDOMINAL AORTA
7.1. Specific aspects
7.1.1. Incidence. In a large population of 13 902 patients, the
two year rate of abdominal aortic VGI was 0.19% after open
surgery vs. 0.16% after EVAR, without a significant difference,
and 0.2% in both elective and non-elective patients.53 On the
basis of 514 patients, the 30 day incidence was 1.6% (95% CI
0.4%e 2.8%), one year incidence 3.6% (95% CI 1.7%e 5.5%),
and two year incidence 4.5% (95% CI 2.4% e 6.6%).131 EGI is
a rare complication, the incidence being < 1%.132 AEnF was
present in 1% e 2% of the reported cases. In an American
multicentre registry including 180 infected stent grafts, 43 EGI
(23.9%) with an AEnF were reported.110 In a multicentre
study, an AEnF occurred in 32 patients (0.08%).133 EVAR after
anastomotic postsurgical pseudoaneurysm was significantly
associated with developing an AEnF.
7.1.2. Clinical presentation. Most patients (70%) with
abdominal VGEI have pain, fever, and leucocytosis; 33% of
patients suffer weight loss, fatigue, or generalised weak-
ness.132 In a systematic review of the literature conducted
in 2016, 216 studies representing 823 patients with AEnF
were compiled.134 Bleeding was the most commonsymptom (71.7%), followed by sepsis (39.7%) and hae-
morrhagic shock (33.1%).
7.1.3. Specific diagnostic modalities. In cases of suspected
AEnF or haemorrhage, gastroduodenoscopy and/or colo-
noscopy are indicated. Polymicrobial Gram negative and
enteric species, Candida spp., or fungi are highly suggestive
of an AEnF.7.2. Treatment options
7.2.1. Conservative treatment. Conservative treatment,
including percutaneous drainage irrigation can be either a
preparation for open surgery at a later stage or a definitive
palliative strategy in patients unfit for open surgery, owing
to comorbidities or their current state of infection (e.g.,
sepsis). For all conservative strategies, long term or lifelong
antimicrobial therapy is important. AEnF or suture line
rupture precludes a conservative approach.135 Conservative
management of abdominal aortic VGI is hardly ever
possible. Persisting septic complications and rupture are the
major drawbacks, with a 30 day mortality rate of 100% in
small series.136
7.2.1.1. Percutaneous drainage. Fluid collections around
the aortic VGEI may be amenable to percutaneous drainage.
This minimally invasive intervention potentially reduces the
local bacterial and infectious burden, and provides directly
obtained specimens for microbiological sampling. Image
guided insertion of a pigtail catheter into the perigraft
space is performed under local anaesthesia. The catheter is
connected to a gravity drainage bag, and repeated saline
irrigation prevents occlusion. Catheter removal can be
considered once drainage output is low and after imaging
confirmation of resolution of the fluid collection. A further
benefit of drainage is the possibility of performing sinog-
raphy to rule out enteric fistula. A 30 day mortality rate of
40% in infrarenal VGEI treated with percutaneous drainage
alone has been reported.137 Its role in the eradication of
aortic VGEI remains controversial.
7.2.1.2. Irrigation. Irrigation of the infected perigraft space
can be started once a drainage catheter has been inserted.
Mainly earlier reports (published before 1997) on the use of
povidone iodine solution, antibiotic solution, gentian violet,
and saline solution are available. A few case reports with
limited follow up data and no comparison of the irrigation
solutions address this technique.138,139
7.2.2. In situ reconstruction. ISR includes complete removal
of the infected material with reconstruction in the infected
field, and can be done with autologous veins, cryopreserved
allografts, rifampicin bonded or silver coated synthetic
grafts, and xenogenous grafts.
7.2.2.1. Specific techniques. For treatment, surgeons need
to decide for each patient individually.Whatever the type of
reconstruction chosen, removal of the infected material is
necessary at a certain point. The first step of this inter-
vention consists of securing the aortic clamping zone.140 For
Table 7. Autologous vein reconstruction of abdominal aortic vascular graft infection: a literature overview
Author Publication
date
Study type n Follow
up
e mo
Early
mortality
e %
Late
mortality
e %
Amputation
rate e %
Graft
occlusion
e %
Re-
infection
e %
Graft
rupture
e %
Cardozo
et al.267
2002 Retrospective 12 22 15.3 15.3 16.7 NA 0 NA
Daenens268 2003 Prospective
database
49 41 8 NA 2 4 0 NA
Beck269 2008 Retrospective 240 59 NA NA NA 6 NA NA
Ali et al.145 2009 Prospective
database
165 32 10 33 7.4 0 5 5
Aavik270 2008 Retrospective 11 59 0 0 18.2 9.1 0 NA
Ehsan and
Gibbons223
2009 Retrospective 46 48 4.3 30 7 9 4 NA
Batt et al.137 2012 Retrospective 6 41 NA NA 0 0 16 NA
Dorweiler
et al.142
2014 Retrospective 67 60 9 55 6 3 0 NA
Charlton-Ouw
et al.177
2015 Retrospective 11 42 0 9 27 NA 14 NA
Heinola
et al.143
2016 Retrospective 55 32 9 40 7 3.6 4 5
NA ¼ not available.
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proposed the use of an intra-aortic balloon inserted via a
femoral approach.141
7.2.2.2. Graft materials.
7.2.2.2.1. Reconstruction with autologous vein. Autologous
veins have the lowest infection rates (0% e 6%) and low
graft thrombosis rates (Table 7). Disadvantages include
harvesting difficulties in the emergency setting and a longer
operation time so that it may not be tolerated by elderly
patients with comorbidities. Previous deep vein thrombosis
is a contraindication.142,143 Harvesting veins is associated
with venous morbidity with chronic venous insufficiency
reported in up to 15%. Deep vein thrombosis occurred in up
to 22%.142,143 Venous grafts might be effective for highly
virulent pathogens, but their use in multiresistant strains
remains unclear.17,142 There are reports of poor outcomes in
the presence of Gram negative micro-organisms, MRSA, or
Candida spp., especially when concomitant sepsis or AEnF
exists.144,145
7.2.2.2.2. Cryopreserved allografts. A number of studies
have employed cryopreserved allografts for ISR of abdom-
inal aortic VEGI.146e153 Cryopreserved allografts have
shown low re-infection rates (0% e 7%). Their limited
availability, and rate of graft related complications resulting
from allograft degradation (up to 21%), including aneurysm,
dilatation, and graft rupture, are the main drawbacks.146e
153 Allograft related re-intervention rates were found in
up to 55% of patients after five years (Table 8).147 However,
a better outcome with no dilatation or aneurysm during a
mean follow up of five years was observed in another series
of 71 patients.154 Survival rates varied between 40% and
54% after five years.147,154
Graft specific factors such as allograft age, pre-treatment,
and cryopreservation were of no prognostic value in
multivariable analysis for ISR with cryopreserved allo-
grafts.150 There is no evidence that post-operativeimmunosuppressive therapy would prevent rejection in
patients with cryopreserved allografts.
7.2.2.2.3. Rifampicin bonded grafts. Rifampicin bonded
grafts can be used in less virulent and low grade infections,
especially if these infections are caused by S. aureus or
coagulase negative staphylococci. The re-infection rate is
11.5% (range 0% e 18%), but the amputation rate is low
(Table 9).17,144,155e158 Experimentally, there is weak activity
against non-fermenter Gram negative bacilli, such as
Pseudomonas species.159,160 In retrospective studies, they
are less effective in infections caused by MRSA, Gram
negative strains, and fungi.156,157 The antimicrobial effi-
ciency of rifampicin bonded grafts is concentration and
time dependent. Owing to dilution, the protective effect is
reduced after approximately one week.157,159 The rifam-
picin bonded concentration currently used in the treatment
solution is heterogeneous, making the prediction of out-
comes impossible. Concentrations of 1 e 60 mg/mL, with a
maximum dose of 600 mg (soaked for 15 e 30 min) have
been used in clinical and in vitro studies.140,144,155,157,159
Development of rifampicin resistance might occur.157
Their major advantage is their off the shelf availability in
the emergency setting.
7.2.2.2.4. Silver coated grafts. Silver coated grafts are
available in two different options, silver acetate, which
dissolves within two to four weeks, and elemental silver,
which remains for about one year.161,162 The advantage of
silver is its wide antimicrobial activity and paucity of resis-
tance development in experimental studies. But in clinical
trials for ISR, the re-infection rate of silver grafts is 11%
(range 0% e 16%) within 2.5 years. Low amputation rates
and high patency rates are reported (Table 10).17,163 There
is no comparison between different silver coatings. Only
one study (n ¼ 10 patients) has reported the effect of
elemental silver graft for ISR in the aorto-iliac position, and
describing one re-infection.164
Table 8. In situ reconstruction with cryopreserved allografts for abdominal aortic vascular graft infection: an overview
Author Publication
date
Study type n Follow
up
e mo
Early
mortality
e %
Late
mortality
e %
Graft related complications
Total
e %
Re-
infection
e %
Aneurysm
dilatation
e %
Rupture
e %
Thrombotic
occlusion
e %
Amputation
e %
Nevelsteen et
al.271
1998 Retrospective 30 25 27 10 NA 7 13 3 23 6.7
Lesèche et al.185 2001 Retrospective 28 35.4 17.8 17.8 17 0 11 0 9 0
Verhelst et al.227 2000 Retrospective 90 36 17 16 21.1 1 7.8 8.8 10 1
Vogt et al.272 2002 Retrospective 49 27 6 20 16.3 0 0 8.1 2 0
Noel et al.273 2002 Registry
database
56 5.3 13 25 25 0 2 9 9 5
Kieffer et al.102 2003 Retrospective 68 34 30 28 20.3 7 NA 0 29.7 0
Bisdas et al.151 2010 Retrospective 57 36 9 36 5.3 0 1.8 1.8 1.8 NA
McCready
et al.228
2011 Retrospective 26 46.6 31 62 19 0 0 0 0 NA
Garot et al.152 2014 Retrospective 18 12 48 48 NA 0 NA NA 23 NA
Touma et al.150 2014 Retrospective 54 12 28 39 19 3.7 1.9 11.1 11.1 1.9
Harlander-Locke
et al.148
2014 Retrospective 220 30 9 49 24 3.6 2.7 5.5 4.1 NA
Minga Lowampa
et al.229
2016 Retrospective 96 49 8 85 29 0 9.4 7 11.7 NA
Heo et al.149 2017 Retrospective 25 19 8 28 12 0 4 4 4 NA
Batt et al.198 2011 Retrospective 21 41 45.5 72.7 NA 14.2 NA NA 18.2 0
Lejay et al.147 2018 Retrospective 25 47 24 40 55 NA 20 24 NA NA
Ben Ahmed
et al.154
2018 Retrospective 71 45 2.8 2.8 18.3 4 0 2 7 1.4
NA ¼ not available.
Table 9. In situ reconstruction with rifampicin bonded grafts for abdominal aortic vascular graft infection: an overview
Author Publication
date
Study type n Rifampicin
dose e
mg/ml
Follow
up
e mo
Early
mortality
e %
Late
mortality
e %
Amputation
rate
e %
Graft
occlusion
e %
Re-
infection
e %
Torsello
et al.158
1997 Retrospective 11 60 33 18 18 0 NA 9
Hayes et al.156 1999 Retrospective 11 45e60 12 18.2 36.4 0 18.2 0
Young et al.155 1999 Retrospective 25 1 36 8 24 0 14 4
Bandyk
et al.157
2001 Retrospective 19 45e60 17 9.1 NA 0 0 8
Oderich
et al.144
2006 Retrospective 52 2.4 41 8 16 0 8.8 11.5
Batt et al.198 2011 Retrospective 8 NA 41 31.8 40 NA 0 0
Schaefers et
al.274
2018 Retrospective 10 NA 27 0 0 NA NA 0
NA ¼ not available.
Table 10. In situ reconstruction with silver coated grafts for abdominal aortic vascular graft infection: an overview
Author Publication
date
Study type Graft
type
n Follow
up
e mo
Early
mortality
e %
Late
mortality
e %
Amputation
rate
e %
Graft
occlusion
e %
Reinfection
e %
Batt et al.275 2003 Prospective Silver
acetate
24 17 16.6 16.6 0 0 0
Mirzaie et al.163 2007 Prospective Silver
acetate
11 30 0 0 0 0 0
Batt et al.276 2008 Prospective Silver
acetate
24 32.5 20.8 25 4 8.3 12.5
Pupka et al.277 2011 Prospective Silver
acetate
27 22.8 11 NA 0 0 16
Bisdas et al.151 2010 Retrospective Silver
acetate
11 24 18 27 0 0 9
Zegelman
et al.164
2013 Retrospective Metallic
silver
10 18 NA NA NA NA 10
NA ¼ not available.
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the shelf solution and can be tailored to form a tube or
bifurcated graft. There are a few case series involving
thoracic, thoraco-abdominal, and abdominal re-
constructions. Re-infection rates were described in up to
16% in small series; other studies reported 100% freedom
from re-infection or re-intervention in follow ups of up to
four years involving thoracic, thoraco-abdominal, and
abdominal reconstructions.113e115,165e168 The largest series
included 35 patients and four years of follow up, and re-
ported only seven patients who got bovine pericardium for
abdominal aortic VGIs. Four of the seven died within 30
days owing to ongoing sepsis and multi-organ failure. Three
were free of re-infection, without signs of degeneration.
Further studies with longer follow ups are mandatory. Their
role in case of sepsis remains unclear.
There is little experience with the use of ovine, mesh
reinforced biosynthetic prosthesis in ISR for abdominal aortic
VGIs (n ¼ 13, follow up 11 e 26 months), with a trend to low
infection rates, but only case series have been reported.169,170
Consequently, no recommendation can be made.
7.2.2.3. Adjunctive therapies. During ISR, the proximal
anastomosis can be re-inforced with fascia.143,171 After
inserting the new VG, it should be covered by biological
material, especially pediculed omentum flap, muscle, fascia,
or retroperitoneal tissue.171 An omental wrap around the
graft lowers the rate of infection, even when rifampicin or
silver coated VGs are used.144,155 There are insufficient data
on the efficacy of bio-absorbable and non-absorbable local
antibiotic beads or sponges, and reported data have
described their use in an extracavity position only.172,173 If
the groin is involved, the distal anastomosis can be covered
by a muscle flap.142,143
The use of NPWT in abdominal aortic VGI has only been
described in five patients with aorto-iliac VGI treated via a
retroperitoneal approach with radical debridement and
placement of the foam directly on the graft. There was no
30 day mortality and no one year re-infection. The tech-
nique requires repeated dressing changes every three to
five days, but long term data are not available.174Table 11. Extra-anatomic reconstructions for abdominal aortic vas
Author Publication
date
Study type n Follow
up
e mo
Early
morta
e %
Seeger et al.175 2000 Prospective 36 32 11
Ohta et al.138 2001 Retrospective 9 47 11
Bandyk et al.157 2001 Retrospective 19 17 9.1
Hart et al.184 2005 Retrospective 15 15 40
Armstrong et al.216 2005 Retrospective 25 51 21
Oderich et al.144 2006 Retrospective 43 41 11.6
Brown et al.176 2009 Retrospective 18 14 22
Batt et al.198 2011 Retrospective 11 41 45
Charlton-ouw
et al.177
2015 Retrospective 5 72 20
Yamanaka et al.183 2014 Retrospective 7 27 NA
NA ¼ not available.7.2.3. Extra-anatomic reconstruction. Axillobifemoral or
axillobipopliteal bypasses through a non-infected field were
performed to restore lower limb perfusion following exci-
sion of an infected graft. The disadvantages of axillobife-
moral reconstructions are low patency rates (64% e 75% at
five years) and high amputation rates (up to 11% at five
years). Stump rupture with life threathening haemorrhage
can occur in up to 27% of reported cases (Table 11).137
Finally, re-infection rates after extra-anatomic bypasses
were 0% e 15%144,175,176 and up to 27% in small se-
ries.137,177 A 30 day mortality rate of 18% (range 11% e
45%) and a late mortality of 32% (range 22% e 44% within
47 months) have been described (Table 11).137,138,175,177,178
Compromised colonic and pelvic blood supply due to
insufficient internal iliac and inferior mesenteric artery
perfusion might also lead to complications.
Axillofemoral and axillopopliteal bypass patency rates
were lower in patients with concomitant occlusive disease
(primary patency of 71% vs. 73%, secondary patency rates
of 79% vs. 92% after five years).175,179 The outcome for
axillopopliteal bypasses in abdominal aortic VGEI is poor,
with a reported primary patency of 0% at 7 months, and a
secondary patency 53% at 17 months and 27% at 50
months in a series of five axillopopliteal bypasses per-
formed for abdominal aortic VGEI.175
7.2.3.1. Two stage procedure. EARs can be performed
directly after bypass removal for reconstruction of the
lower extremities or as staged procedure. A two stage
procedure one to five days before removal of the infected
graft should be considered in haemodynamically stable
patients because of the reduction of operative metabolic
(acidosis) and haemodynamic stress.175,179,180 Reductions
in the mortality and amputation rates were found when
staged procedures were performed.181 Competitive flow
has never been reported to be the causative factor of
graft occlusions, but no specific studies have been
performed.
7.2.3.2. Stump management. Risk of stump rupture is
related to the mechanical consequences of too short a
stump and to the properties of the persistent infectedcular graft infection: literature overview
lity
Late
mortality
e %
Amputation
rate
e %
Graft
occlusion
e %
Re-
infection
e %
Stump
rupture
e %
44 11 31 3 3
22 NA 33 0 0
NA 11 34.4 2.8 NA
45 6 NA 13 7
NA 6.9 NA 13.8 4
NA 9 37.2 11.6 9
44 6 11 0 0
NA 27 27 27 27
40 0 NA 20 20
NA 6.9 NA 13.8 NA
366 Nabil Chakfé et al.tissue after incomplete debridement. If the stump is too
short, transposition or renal and visceral artery bypass is
likely to be necessary and should be performed first to
minimise the visceral ischaemic time. Techniques to prevent
stump rupture include double suture layers, reinforcement
with venous or felt pledgets, prevertebral fascia, or a layer
of posterior rectus fascia peritoneum. Most authors
recommend covering the stump with omentum or an
omental wrap.144,178,182 Another technique is a pedicled
latissimus dorsi flap.183
7.2.4. Systematic reviews and meta-analyses on in situ
reconstruction, extra-anatomic reconstruction, and graft
materials. Two meta-analyses (37 studies, 1 417 patients;180
36 studies, 1 464 patients17) showed significantly better
outcomes for ISR than EAR with overall lower complication,
re-infection, and mortality rates.
There was no significant difference in the re-infection
rate between the different grafts (veins 2%; cryopreserved
allografts 9%, rifampicin bonded or silver coated prosthesis
11%), but they all demonstrated significantly better results
than standard ePTFE and PET grafts for ISR. Veins and silver
coated prostheses had significantly lower graft occlusion
rates (2% and 7%, respectively) than cryopreserved allo-
grafts (13%) or rifampicin bonded prostheses (11%). The
amputation rate was significantly lower in cryopreserved
allografts (3%), and rifampicin (3%) or silver coated grafts
(4%) than veins (9%). Standard ePTFE and PETgrafts gave
significantly worse results for graft occlusion and amputa-
tion. Meta-regression analysis preferred veins for ISR neo-
aorto-iliac reconstruction, especially in younger patients,
except in the presence of AEnF, while autologous veins
provided the best outcomes with virulent infecting
organisms.
For abdominal aortic VGEI without AEnF, the data suggest
that ISR with autologous veins, cryopreserved allografts,
silver coated grafts, or rifampicin bonded grafts should be
considered. Long term follow up is missing for bovine
pericardium. Even though there is no ideal graft material,
most authors prefer a biological material conduit for ISR.
Veins might be preferable in young patients with a longer
life expectancy. Rifampicin soaked grafts or silver grafts
have been shown effective, especially in low virulence in-
fections. For large perigraft abscesses and MRSA infections,
EAR and removal of the infected graft may be
considered.17,146,151,176,177,180
7.2.5. Partial or total excision of the material. Total excision
of the infected graft is mandatory to control VGI.148 There
are some inconclusive reports of partial graft resection in
high risk patients, when complete graft excision was not
possible.184 In retrospective studies, successful treatments
were reported, when infection was limited to the groin and
supra-inguinal VGs were incorporated. Retrospective
studies reported no re-infection after 2.5 years in 11 pa-
tients after interposition of unilateral silver coated grafts,163
no re-infection after partial interposition withcryopreserved allografts in 10 patients after three years,185
and a 9.5% re-infection rate after partial resection with
autologous vein interposition in 20 patients after 72
months.186 Limited resection of only infected material and
reconstruction by obturator canal bypass (n ¼ 18) or part of
a bifurcated graft (n ¼ 34) was also proposed with re-
infection rates of 6% and 0%, respectively, and no ampu-
tation at 36 months.187 Other series reported a 47% (n ¼ 7/
15 patients) infection rate of the contralateral limb after 39
months, when partial resection of an aortobifemoral VGI
and EAR was performed.188 Overall mortality was 40% and
similar between patients with or without recurrent graft
infections.
As an individual decision, partial resection, and ISR or an
extra-anatomic route might be an option. Successful treat-
ment was based on low virulence organisms, especially
monomicrobial determination of multidrug sensitive strep-
tococci species and S. aureus. If polymicrobial, fungal or
Gram negative organisms were present, total excision of the
infected graft was recommended.163,186e188
7.2.6. Endograft infection. Eradication of infection by
removal of the infected EG and ISR with biological material
has the lowest re-infection rate (< 10%) and is recom-
mended for patients who are fit for surgery.132 Reported 30
day mortality rates have been 8% e 39% and amputation
rates 0% e 2%.189e191 In the case of EAR, stump manage-
ment may be more difficult because clearly the neck can be
damaged by the extraction owing to the presence of su-
prarenal hooks promoting ligation very proximal to the
renal artery ostia. If the patient is unfit for surgery, con-
servative treatment with lifelong antibiotics or drainage of
infection without removal of the EG must be considered.
The mortality of patients managed by conservative treat-
ment with antimicrobial therapy alone is high, reported as
63.3% at 30 days.1327.3. Graft enteric fistula
Fistulisation can occur early after bowel injury during the
surgical dissection or poor tunnelling, or as a consequence
of a suture line pseudo-aneurysm or as a consequence of
prior graft infection.192
7.3.1. Specific treatment modalities. Depending on the
location of the AEnF, securing the aortic clamping zone can
be obtained more proximally using a supracoeliac
approach.140,192 Whenever possible, it is advised to avoid
entering the enteric communication during the dissection
and to leave a “patch” of the old graft attached to the
intestine to avoid enteric content spillage.140
7.3.2. Stent grafts as a temporary or a definitive solution.
In the last decade, several studies have reported the use of
stent grafts to treat AEnF. In a retrospective comparative,
multicentre study no post-operative mortality in patients
treated with EG vs. VG, a mortality of 35% in patients
treated with VG was reported.193 Late sepsis occurs
ESVS 2020 Management Guidelines for Vascular Graft and Endograft Infections 367significantly more often after endovascular surgery than
after open surgery (42% vs. 19% at two years). In particular,
the presence of pre-operative sepsis was found to be a
factor indicative of an unfavourable outcome.193 As a
consequence, some authors have proposed the temporary
use of EG as a “bridge technique” followed by EG extraction
and in situ repair, or even as a definitive treatment in select
cases of bleeding without clear sepsis.194e198
7.3.3. In situ reconstruction or extra-anatomic recon-
struction. A systematic review based on 1 467 patients
concluded that axillobifemoral bypass and abdominal aortic
VG removal in a staged procedure was the best therapeutic
option, with a mortality of 31% vs. 51% in a non-staged
procedure and 47% in the case of ISR.199 No difference in
re-infection rate between EAR and ISR was found.198 In both
cases, PET VGs were used. These findings contrast with
other findings that report ISR as an independent factor for
survival in a multivariable analysis.200
7.3.4. Total or partial graft excision. In a series of 54 pa-
tients treated for a secondary AEnF, partial graft excision led
to a 4% re-infection rate with a mean follow up of 51
months.140 In several studies, no difference in outcome was
seen between patients with partial resection and complete
resection.146,198 The only factor influencing the re-infection
rate (47%) was the length of follow up, led to the conclusion
that lifetime follow up was mandatory.198 Mortality after re-
infection was 100%.
7.3.5. Bowel repair
7.3.5.1. Direct suture vs. complex bowel reconstruction.
The type of the bowel repair depends on the size and the
location of the defect.140,192,201 A tension free duodenor-
rhaphy with direct suture of the duodenum can be per-
formed if the bowel defect is small, avoiding an extensive
approach, but a complex duodenal reconstruction with
resection anastomosis and re-routing decreases the risk of
recurrent infection.200
7.3.5.2. Omental interposition. Pedicle omental flap can be
transferred in order to cover the reconstruction and sepa-
rate the new vascular reconstruction from the bowel. It is
recommended when feasible as it has been shown to be the
strongest predicitive factor for survival.140,192,200,2017.4. Visceral artery revascularisation infection
Although the nature of the bypass suggests that visceral by-
passes are frequently involved with VGEI, a systematic litera-
ture search yielded only two case reports that specifically deal
with the treatment of an infected mesenteric bypass.202,203
Owing to the optimisation of endovascular possibilities,
the treatment of mesenteric occlusive disease has evolved
towards an endovascular first approach whereas in the
recent past this was not the case. In some cases of infected
mesenteric bypasses, an initial endovascular recanalisation of
the native vessel followed by removal of the infected graft
material and closure of the anastomotic site with an autol-
ogous vein patch might be possible.2027.5. Ureteral fistula
Arterio-ureteral fistulae (AUFs) occur in < 1% of patients
after aorto-iliac surgery and are almost entirely related to
VGIs. A pseudo- or true common or external iliac artery
aneurysm with fever, pain, or swelling due to abscess can be
found in 38% of cases.204 Recurrent urinary tract infections
were concomitant findings in 40% and urinary outflow
obstruction with hydronephrosis in 70%.205e207
For acute haemorrhage, stent graft insertion as a bridge
might be proposed.206 For definitive healing, open surgery
with VG or EG explantation and AUF resection is mandatory.
VG or EG removal and EAR with femorofemoral crossover
bypass and ligation of the iliac artery should be consid-
ered.205e208 In ISR with cryopreserved allografts, silver
coated or rifampicin bonded VG were reported, but there
are no available data concerning morbidity or mortality
rates. Primary ureteric repair, ligation (with or without ne-
phrectomy), re-implantation to a site away from the vessels,
or diversion of the urine with a nephrostomy tube may be
necessary. Nephrectomy has to be considered if irreversible
damage to the renal collecting system has occurred.205e208
An indwelling ureteral stent should be removed owing to
the risk of recurrent fistulisation or re-infection.2077.6. Follow up and prognosis
Abdominal aortic VGEI are some of the most challenging and
highly morbid conditions to treat, with an early mortality rate
ranging from 16% to 22%, an amputation rate ranging from
3% to 18%, and a re-infection rate of 6% e 20%.17,137
However, late mortality is not assessable owing to insuffi-
cient data, a wide range of follow up, and the use of different
types of conduit. Because it is a rare condition, studies
include all kind of abdomino-iliac or aortofemoral graft
reconstruction. Therefore, there is very limited evidence, with
no comparative studies at all and with most published series
burdened by seletion bias, indicating that individual surgical
decisions for treatment are needed (Fig. 6).
Management and treatment choice must be performed
within a multidisciplinary team, including vascular surgeons,
visceral surgeons, infection disease specialists, radiologists,
and anaesthetists.
Mortality rates relate to: (i) the patient’s condition e an
American Society of Anaesthesiology score 4 and sepsis are
independant risk factors for mortality,145,154 as well as indi-
vidual local presentation of infection affect the outcome; (ii)
the emergency or elective setting e there is higher 30 day
mortality in emergency settings;146 (iii) the presence of an AEnF
e studies that included AEnF resulted in worse outcome;198 (iv)
virulence of the micro-organisms e operative mortality rate
was higher in abdominal aortic VEGI caused by virulent micro-
organisms.17,144,145,156,157,180 MRSA and multiresistant strains
are associated with poor outcome.17,137,144,156,157,180
Post-operative duration of antibiotics and the variety of
bacterial specimens are quite different. The number of
studies and wide range of included patients (n ¼ 5e220)
might not adequately represent diverse patterns of clinical
manifestation, specific patient subgroups or the experience
Recommendation 39
For patients with an abdominal aortic vascular graft/
endograft infection, in situ reconstruction with autologous
vein should be considered as the preferred method.
Class Level References
IIa C Batt et al. (2018),17
Spiliotopoulos et al. (2018),66
Dorigo et al. (2003),69 Dorweiler
142
Abdominal aortic VGEI
Acute bleeding
No
No
No fistula
Graft explantation
*
Conservative or palliative
treatment
Antibiotics
Drainage
Irrigation
Prolonged antibiotics
Long-term follow-up
Vascular reconstruction
In situ 1st choice†
Extra-anatomical omentoplasty
Consider endograft if
Limited signs of infection
High operative risk of resection
Bowel repair
Aorto-enteric fistula
Yes
Yes
Consider bridge treatment
with endograft
Fit for surgery
Figure 6. Proposed algorithm for the management of aortic vascular graft/endograft infection. * In a single or staged prodecure. y Materials
that can be used are deep femoral veins, cryoprerved allografts, silver grafts or rifampicin impregnated grafts. VGEI ¼ vascular graft/
endograft infection.
368 Nabil Chakfé et al.of each centre because of the low numbers of patients
treated annually.
Post-operative follow up is important. Close surveillance,
including laboratory test and US is mandatory every three to
six months for a minimum of one year, and later lifelong
every 6 e 12 months is reasonable. If clinical signs, labora-
tory tests or US are suspicious, CT is recommended. Special
attention should be paid if ISR with allografts was performed.Recommendation 38
For fit patients with an abdominal aortic vascular graft/
endograft infection, complete excision of all graft material
and infected tissue is recommended for definitive treatment.
Class Level References
I B Batt et al. (2018),17 O’Connor et
al. (2006)180
Recommendation 37
Percutaneous drainage of peri-graft fluid with or without
irrigation may be considered for microbiological identification
and to reduce the bacteriological burden, but not as ultimate
treatment in abdominal aortic graft/endograft infection.
Class Level References
IIb C Calligaro et al. (2003),135 Batt
et al. (2012),137 Ohta et al.
(2001),138 Igari et al. (2014)139
et al. (2014), Heinola et al.
(2016),143 Ali et al. (2009),145
Harlander-Locke et al. (2014),148
O’Connor et al. (2006),180
Rodrigues dos Santos et al.
(2014)200
Recommendation 40
For patients with abdominal aortic vascular graft/endograft
infection, cryopreserved allografts, silver coated grafts,
rifampicin bonded polyester grafts, or bovine pericardium
should be considered as alternative solutions.
Class Level References
IIa C Batt et al. (2018),17
Spiliotopoulos et al. (2018),66
Dorigo et al. (2003),69
Dorweiler et al. (2014),142
Heinola et al. (2016),143 Ali
et al. (2009),145 Harlander-
Locke et al. (2014),148 O’Connor
et al. (2006),180 Rodrigues dos
Santos et al. (2014)200
Recommendation 41
Partial excision of infected an aortic vascular graft/endograft
may be considered when infection is documented as limited
and the remaining material is well incorporated.
Class Level References
IIb C Mirzaie et al. (2007),163
Simmons et al. (2017),186
Phang et al. (2019)187
Recommendation 42
For patients with abdominal aortic vascular graft/endograft
infection and a large abscess or multiresistant micro-
organisms, extra-anatomic reconstruction may be considered.
Class Level References
IIb B Oderich et al. (2006)144
Recommendation 43
Lifelong imaging follow up is recommended after in situ
reconstruction with cryopreserved allografts for abdominal
aortic vascular graft/endograft infection, in order to detect
allograft degeneration.
Class Level References
I C Lejay et al. (2017),147 Harlander-
Locke et al. (2014),148 Touma
et al. (2014),150 Kieffer et al.
(2004),153
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Securing a supracoeliac clamp zone or using an aortic
occlusion balloon may be considered as the first step before
entering the aorto-enteric fistula area.Class Level ReferencesIIb C Miyamoto et al. (2016),141
Schoell et al. (2015)192Recommendation 45
In the emergency setting of active bleeding complicating
abdominal aortic graft/endograft infection with or without
aorto-enteric fistula, initial treatment with an endograft
should be considered, but only as a temporary measure.Class Level ReferencesIIa C Chick et al. (2017),197 Batt et al.
(2011)198Recommendation 46
In surgical repair of aortic abdominal graft/endograft
infection with aorto-enteric fistula, omentoplasty or
transfer of autologous vascularised tissue to cover the
vascular reconstruction is recommended.Class Level ReferencesI B Rodrigues dos Santos et al.
(2014)200Recommendation 47
In the emergency setting of active bleeding complicating
abdominal aortic graft/endograft infection with an arterio-
ureteral fistula, initial treatment with an endograft may be
considered, but only as a temporary measure.Class Level ReferencesIIb C van den Bergh et al. (2009),204
Das et al. (2016),205 Malgor
et al. (2012),206 Madoff et al.
(2004),207 Pillai et al. (2015)208Recommendation 48
For patients with an arterio-ureteral fistula and vascular
graft/endograft infection, complete explantation of the
graft combined with urological treatment with or without
in situ arterial reconstruction should be considered.Class Level ReferencesIIa C van den Bergh et al. (2009),204
Das et al. (2016),205 Malgor et
al. (2012),206 Madoff et al.
(2004),207 Pillai et al. (2015)2088. PERIPHERAL ARTERIES
8.1. Specific aspects
8.1.1. Incidence and risk factors. VGI has been reported in
up to 2.5% in femorofemoral prosthetic bypasses,209 and in
up to 2.8% in femoropopliteal prosthetic bypasses.210
Higher incidences have been reported in series where
90% of the indication had been critical limb threatening
ischaemia. In a retrospective review of 141 grafts involving
the femoral artery, VGI occurred in 25 (18%) and occurred
most frequently after major amputation (41% vs. 6%) or
early re-intervention after initial grafting (70% vs. 16%). Risk
of VGI after amputation was highest when amputation was
performed less than four weeks after the bypass (70% vs.
32% when amputation was done more than four weeks
after the bypass).211
The differentiation of deep wound infection and VGI is
unclear in many reports. SSI is the strongest risk factor for
VGI. Risk factors for SSI must be known, but it should always
keep in mind that these are not strictly correlated with VGI
(Table 12).
Peripheral arteries are a major site for stent implantation.
One systematic review identified 48 bare metal stent in-
fections outside the coronary arteries.212 Emergency prior
procedures with adjunctive thrombolysis represented
almost 20% of the infected non-cardiac cases and were
considered as risk factors for infection.
8.1.2. Clinical presentation. The most common site of VGEI
after aorto-iliac or infra-inguinal reconstructions is the
groin. Clinical presentation can include fever, pain, mass,
or redness of the skin. This can be explained not only by
the specific risk of contamination of the groin or by the
370 Nabil Chakfé et al.poor healing of the wound, but also because this
approach is frequently performed in patients with infec-
ted distal wounds. Wound complications following
vascular procedures involving the groin have been re-
ported in up to 20% of patients.2138.2. Treatment options
8.2.1. Conservative treatment. Conservative treatment of
lower limb VGI without removal of the infected VG is
rarely an option because it is associated with a high
mortality (up to 45% at five years),214 persistent infection,
anastomotic disruption, or active bleeding. However, if the
infected VG is not removed, the risk of persistent infec-
tion, anastomotic disruption, or active bleeding must be
anticipated.
8.2.1.1. Negative pressure wound therapy. NPWT is an
option to manage VGI in order to promote wound healing
after debridement of the infected tissue.215 Even though
e125 mmHg has been shown to allow faster granulation
and faster healing, lower pressure is recommended if the
NPWT is in contact with the graft in order to avoid the
bleeding when higher pressure is employed.215 NPWT
may lead to serious bleeding complications in up to 10%
of patients and eradication of infection is uncertain.216e
220
In a retrospective series of 68 patients with 72 deep
inguinal infections below the inguinal ligament and with a
blood culture negative for septicaemia, septic anastomotic
involvement, or bleeding, 85% (n ¼ 61/72) of the grafts
were in place nine months after initiation of treatment.215
Another retrospective study of 161 patients treated by
NPWT showed that major bleeding occurred in 7.1% and re-
infection after complete wound healing in 6.4%. The cu-
mulative estimated proportion of completely healed
wounds was 70% after 80 days. Independent risk factors for
failure of wound treatment were synthetic graft infection
(OR 6.1, 95% CI 2.6 e 14.2) and bleeding or pseudo-
aneurysm as presenting symptom (OR 2.9, 95% CI 1.0 e
8.2).218Table 12. Patient related independent risk factors for surgical site
Risk factor Adjusted
OR (95%
Female sex 1.44 (1.2
Obesity 2.08 (1.7
Body mass index >25 kg/m2 1.78 (1.2
Chronic obstructive pulmonary disease 4.29 (2.7
Dialysis 2.10 (1.0
1.51 (1.0
Critical limb ischaemia 4.35 (3.4
Re-intervention 2.91 (1.6
Blood glucose >11 mmol/L 2.68 (1.3
Hyponatraemia <134 g/dL 11.0 (1.9
Post-operative immobilisation 1.20 (1.0
Major amputation 12 (4.1e
Prior revascularisation 2.68 (1.3
OR ¼ odds ratio; CI ¼ confidence interval.The EndoVAC technique can be an option for bleeding or
high risk of bleeding.84,85 The principle in this hybrid tech-
nique is to use endograft to control or prevent bleeding and
NWPT for secondary wound healing, but so far the number
of patients treated is too low to give any recommendations
on the use of this technique.
8.2.1.2. Irrigation. The aim of irrigation is to reduce bac-
terial colonisation of the infected VG. Irrigation is mostly
established in the groin, through drainage provided by a
tube placed in the infected cavity after wound debride-
ment. Irrigation may be considered only in patients in
whom removal of the infected prosthetic material is not
possible.213
8.2.2. In situ reconstruction
8.2.2.1. Specific technical aspects. If the original indication
was claudication, immediate revascularisation may not be
necessary. In these cases, arteriotomies performed for VG
removal must be closed with biological substitutes, such
as saphenous vein or bovine pericardial patch. A second-
ary bypass may be performed later after total eradication
of the infection. Conversely if the original indication
was chronic limb threatening ischaemia (Rutherford 4 e 6)
and if the leg presents with severe ischaemia after VG
removal, immediate redo bypass is mandatory to avoid
major amputation. Revascularisation is also needed when
the arterial disease has progressed significantly or infected
graft removal is not possible without sacrificing other
crucial vessels.
8.2.2.2. Graft materials.
8.2.2.2.1. Reconstruction with autologous material. The
great saphenous vein (GSV) and other superficial venous
materials is preferred when available, as such material is
easily harvested.221,222
Autologous femoral vein has also been reported to be
useful in treating peripheral graft infections with a low rate
of recurrent infection, if the diameter of the femoral vein
fits the inflow and outflow arteries.223
ISR, preferably with autologous vein, has gained popu-
larity as it is less invasive than extra-anatomoticinfections of the lower limbs
risk estimation
CI)
Reference
8e1.63) Greenblatt et al. (2011)278
8e2.43) Greenblatt et al. (2011)278
3e2.57) Davis et al. (2017)279
4e6.72) Davis et al. (2017)279
7e4.09) Leekha et al. (2016)280
8e1.44) Greenblatt et al. (2011)278
5e5.47) Davis et al. (2017)279
1e5.27) Leekha et al. (2016)280
8e5.22) Leekha et al. (2016)280
e63) Brothers et al. (2009)211
2e1.42) Greenblatt et al. (2011)278
34) Brothers et al. (2009)211
8e5.22) Leekha et al. (2016)280
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remains controversy over which is the optimal ISR graft
following excision of the infected graft.
8.2.2.2.2. Cryopreserved allografts. The re-infection rate of
ISR with cryopreserved allograft is lower than with pros-
thetic grafts, and the amputation rate is lower than with
the removal of the infected graft without reconstruc-
tion.147,223,226e228 However, graft degeneration may lead
to serious complications in the long term. In a retrospec-
tive analysis of 53 patients treated for VGI with cry-
opreserved arterial allograft, the graft related re-
intervention rate at five years was 33% in patients who
underwent peripheral reconstruction (two allograft rup-
tures, seven aneurysmal degenerations). Allograft related
complications, such as allograft thrombosis, anastomotic
pseudo-aneurysm, degenerative aneurysm, and allograft
disruption leading to bleeding have been reported in 29%
of patients.229 Cryopreserved GSV has the advantage of a
better size match in the infrapopliteal segments and crural
vessels and longer segments may be available than ar-
teries; however, patency is limited (around 35% at one
year).230 Primary and secondary patency rates of 56% and
73% have been reported at one year, respectively, and 17%
and 38%, respectively, at five years.231
8.2.2.2.3. Prosthetic grafts. The advantages of prostheses
are that they are readily available and operating time is
shorter, but the re-infection rate is high vs. non-
prosthetic solutions. Silver impregnated or rifampicin
soaked PET grafts have been used for ISR following
removal of the infected graft, but the level of evidence is
low and most of the studies have been on the treatment
of aortic infection.232,233 In a study of 24 femoropopliteal
bypasses replaced with silver impregnated PET grafts, the
overall re-infection rate was 19%.234 When rifampicin
soaked grafts are used, the results of wound cultures
(when available) should be considered, as data have
shown that the micro-organism causing the infection was
resistant or not susceptible to rifampicin in 31% of
cases.235
A biosynthetic collagen prosthesis (Omniflow II; LeMaitre,
Burlington, MA, USA) has also been tested in the presence
of graft infection. In a series of nine consecutive patients
who underwent replacement of an infected peripheral graft
with a biosynthetic prosthesis, the early morbidity rate was
56% (n ¼ 5), with no in hospital death. Four patients had
post-operative wound healing problems treated conserva-
tively and one patient had acute early graft occlusion
leading to major amputation. Two patients had late graft
occlusion six and 12 months after the procedure, respec-
tively. FDG-PET was performed in six patients after a median
follow up of 19 months, which excluded graft re-infection in
all patients.236
8.2.2.2.4. Xenogenous grafts. Bovine pericardial patches can
also be used to replace an infected patch or close the
arterial defect. They are are supposed to be more resistant
to infection than prosthesis.237 In a series of 51 bovinepericardial patches used to close an arteriotomy where the
original ePTFE patch had to be removed as a result of
infection, one rupture was reported, but no other infection
related complication occurred after a median follow up of
25 months.237
8.2.2.3. Adjunctive therapy. A growing body of research and
experience suggests that muscle flap coverage in addition to
graft removal with or without vascular reconstruction can be
efficacious in managing these complex groin wounds and
improve graft and limb salvage and survival. Several retro-
spective studies support the use of different types of muscle
flaps in high risk vascular surgery patients, and report
decreased groin wound morbidity.238e240 However, more
data are required to see clearly which type of muscle flap is
ideal in which type of wound.
8.2.2.3.1. Sartorius muscle flap (SMF). SMF has been
considered the standard surgical technique to treat infec-
tious complications in the groin, in addition to a simulta-
neous vascular procedure.238 There were concerns about
sartorius muscle arterial blood supply in cases with su-
perficial femoral artery occlusion, as sartorius arterial blood
supply originates from multiple segmental branches of the
superficial femoral and deep femoral artery. When the
deep femoral artery is patent, the patency of superficial
femoral artery does not affect the viability of the
SMF.241,242 However, SMF viability is compromised when
the deep femoral artery is occluded. In such cases, revas-
cularisation of the deep femoral artery is needed, either
directly or indirectly (obturator bypass). In a series of 170
SMFs, of which 36 (21%) were done for infection, surgical
re-intervention within 30 days was required in seven of 170
patients (4.1%) and any 30 day complications occurred in
47 patients (28%).243 Another study compared efficacy
analysis of the SMF vs. the rectus femoris flap (RFF) in the
treatment of wounds following an infra-inguinal vascular
procedure in 184 patients and a total of 201 flaps. There
were no sentinel bleeding events through the course of
graft salvage or peri-operative morbidity beyond local
wound complications.244
8.2.2.3.2. Rectus femoris flap (RFF). A RFF is easy to harvest,
has a good blood supply from the lateral circumflex femoral
artery, has an excellent arc of rotation, and provides a large
bulk to fill larger defects after aggressive debridement for
infected and necrotic tissue. With a smaller donor site
incision, the morbidity of the procedure can be decreased
further.239 There was no statistically significant difference in
complications or graft salvage rates comparing the RFF with
the SMF.244
8.2.2.3.3. Gracilis muscle flap (GMF). The retroflexed GMF
has been reported to have a high rate of healing for
complex infected groin wounds, even in the presence of a
synthetic conduit. It is technically easy to perform and it
can be accomplished safely, with a high rate of complete
healing.245 A prospective study reported a 24 month
outcome of 22 patients who underwent GMF after com-
plications resulted from arterial bypass surgery: 45% of
372 Nabil Chakfé et al.patients presented with graft infection, 50% with wound
dehiscence, and 5% with graft disruption and bleeding. At
one month, 54% of wounds were healed and 100% at
three months with adjunctive NPWT and lifelong
antibiotics.246
8.2.2.3.4. Rectus abdominis flap (RAF). When skin closure
of the groin wound is desired and impossible following
debridement and after infection control, RAF may pro-
vide excellent soft tissue coverage with different varia-
tions of skin paddle design. This flap has reliable
anatomy, with an arc of motion that can address complex
defects of the groin. Although flap transfer is highly
successful, significant donor site problems, including
abdominal hernia, abdominal laxity, and groin hernia
have been reported.
8.2.2.3.5. Musculocutaneous anterolateral thigh flap. The
musculocutaneous anterolateral thigh flap has been re-
ported to have fewer donor site complications and can be
used if the flap inflow is not compromised by previous
operations.247,248 In a retrospective study of 39 patients
who underwent 30 musculocutaneous anterolateral thigh
flaps and 10 RAF procedures, all flap recipient sites healed.
Early post-operative complication rates (such as haemato-
mas, surgical site infections, flap dehiscence, or skin graft
necrosis) were similar in both groups. Musculocutaneous
anterolateral thigh flap patients had a shorter time to
healing and fewer post-operative complications than RAF
patients.247
8.2.2.3.6. Antibiotic loaded beads. Antibiotic loaded beads
can be implanted adjacent to the infected VG after wound
debridement and antibacterial irrigation.173,249,250 Different
types of beads are available, including vancomycin, tobra-
mycin, and gentamicin, or a combination thereof.250 Con-
servative treatment can allow complete healing, but re-
infection rates following irrigation with antibiotic beads of
up to 20% have been reported.173,250 In a retrospective
series of 34 patients (36 limbs) with SSI treated with anti-
biotic loaded polymethylmethacrylate beads, the lower
extremity bypass graft was preserved in 28 limbs and ISR
was performed in eight. After a median follow up of 17
months, limb loss was 21.4% and the recurrent infection
rate was 19.4%.173
8.2.3. Extra-anatomic reconstruction. To avoid routing in an
infected area or in multi-operated areas, extra-anatomic
routing may be mandatory. Extra-anatomic routing is
particularly suggested when MRSA, Pseudomonas, or
multidrug resistant bacteria are present.
8.2.3.1. Obturator bypass (OB). OB is used to bypass
infection in the groin. The inflow vessel is the intact external
iliac artery and the outflow vessel is the distal superficial
femoral artery (SFA) or less frequently, the distal deep
femoral artery.251 In a recent retrospective study, 15 pa-
tients underwent 18 OBs with a polytetrafluoroethylene
(PTFE) prosthesis. Indications for surgery were chronic
infection in 10 patients and acute bleeding in five. Midtermoutcomes included five late deaths and one myocardial
infarction. Three patients underwent above knee amputa-
tion in the 58 months of follow up. Another procedure was
required in 11 (61%) limbs. One OB (6%) became infected,
requiring removal at 42 months. Primary, primary assisted,
and secondary patency rates were 65%, 71%, and 88% at 24
months, respectively.252 The autologous femoral vein pro-
vides an excellent size match and a suitable length for
OB.253
8.2.3.2. Lateral retrosartorius bypass (LRSB). As an alter-
native route to OB, case reports have been published on
LRSB when routing of the graft from the external iliac
artery to the distal SFA is needed.254 The infected area in
the groin may affect the approach to the distal anasto-
mosis on the deep femoral artery. A useful technique is to
perform the dissection lateral to the sartorius muscle a
few centimeters distal to the contaminated wound be-
tween healthy tissues.255 In a recent series of 16 patients
with VGI in the groin, 19 lateral femoral bypasses were
performed. Three patients were operated on urgently for
acute bleeding. The new bypass conduit was tunnelled
laterally in the clean tissue, medial to the anterior supe-
rior iliac spine, and under the inguinal ligament through
the psoas canal. The ipsilateral iliac artery was used as an
inflow artery and deep femoral artery or SFA as the target
distal vessel. Choice of conduit included six (32%) autog-
enous vein grafts, 10 (53%) allografts, two (11%) rifam-
picin soaked PET grafts, and one (5.3%) ePTFE graft. Two
year primary assisted patency and limb salvage rates were
83% and 93.9%, respectively.256
8.2.3.3. Perigeniculate arteries (PGAs). PGAs may be useful
if the standard exploration of the popliteal artery and the
crural vessels is not possible because of infection. If the
PGAs have an adequate diameter, they can be used for
distal revascularisations.257 A series of 47 bypasses with the
distal anastomosis to the descending genicular artery (n ¼
25) or medial sural artery (n ¼ 24) reported peri-operative
mortality and amputation rates of 8.5% and 21.3%,
respectively. Three year secondary patency, limb salvage,
and overall survival rates were respectively, 83%, 74%, and
77%.257
8.2.3.4. Lateral approach to crural arteries (LACA). Finally,
the LACA represents a simple solution to threatened limbs
in otherwise difficult situations and LACA may be the ideal
approach for vein grafts to the anterior tibial and distal
peroneal arteries via a lateral tunnel far away from the
infected tissues and with acceptable patency rates.258 In a
series of 21 patients who underwent 23 bypasses for limb
salvage (10 due to infection), a LACA approach and subcu-
taneous graft tunnelling with autologous vein (n ¼ 21) and
PTFE (n ¼ 2) was reported. The distal anastomosis was done
to anterior tibial artery (n ¼ 16), peroneal artery (n ¼ 3),
above knee popliteal artery (n ¼ 3), and dorsalis pedis (n ¼
1). There were three early (13%) and four late (17%) bypass
occlusions. The primary patency at one year was 61% and
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required.258
8.2.4. Total or partial graft explantation and need for
revascularisation. For total explantation without revascu-
larisation, arteriotomies performed for VG removal must be
closed with biological substitutes, such as saphenous vein
or pericardial patch. A secondary bypass can be performed
later after total eradication of the infection.
If the VG is well incorporated and does not have any
obvious contamination, explantation of the whole graft may
not be necessary.259 The infected part of the VG is usually
unattached to the surrounding tissue, allowing for easy
removal. The removed part should be replaced with autog-
enous vein or biological graft material (see 8.2.2.2). Using
this approach, elimination of the infection, preservation of
limb perfusion, and long term survival are achieved in at
most, 70% e 80% of patients presenting with VGI.225,260,261
Of the 27 patients who underwent 30 partial PTFE graft
explantations, re-infection occurred in 15% during a 27
month follow up.262 In another series of 86 extracavity VGIs
(initial procedure: 24 aortobifemoral bypasses; 19 extra-
anatomic bypasses; 31 infra-inguinal bypasses; and 12 com-
bined outflow/inflow reconstructions) the graft was pre-
served in three patients, graft excision and extra-anatomic
bypass was performed in four patients, and graft was
removed and replaced with ISR in 79 patients (rifampicin
bonded PTFE n ¼ 22, autologous conduit n ¼ 57). Recurrent
SSIs occurred in 66% of patients treated initially with graft
preservation and 14% of patients receiving rifampicin
bonded ISR and in one patient who had an isolated segment
of retained PET graft from a previous bypass procedure. One
early and five late re-infections (mean interval of 23 months)
were reported. Re-infection rates by life table estimate were
2.3% and 8% at one and five years, respectively.216
Although several studies have suggested equivalent rates
of re-infection and sepsis after partial or complete resection
of infected lower extremity bypasses, these patients should
be under surveillance until the infection has been eradi-
cated and the wounds are healed owing to the possibility of
recurrent infection in the remaining graft.157,262,263 Conse-
quently, the combination of leaving minimal VG in the
surgical field, aggressive irrigation, and antimicrobial ther-
apy may alleviate the risk of further infection.262 The
treatment modality should be tailored to the patient’s
condition, to the availability of autologous vein, cry-
opreserved allograft or an alternative vascular conduit, and
to the surgeon’s experience.260,264,265
8.2.5. Timing of surgery. Procedures to treat VGI should take
place without delay. For any bleeding from an anastomosis,
there is a possibility of massive bleeding and the patient
should be operated on on an on call basis. Also, abscesses
should be drained and devitalised tissue resected within a
few hours. Infected graft material should be resected during
the same procedure. If there is no critical limb threatening
ischaemia after the graft resection, secondary revascularisa-
tion may be delayed until the wounds have healed.8.3. Follow up and prognosis
Peripheral VGI is always a serious condition with high risk of
amputation and re-infection if all prosthetic material cannot
be removed. Surveillance is usually needed not only
because of underlying severe lower limb arterial disease,
but also to exclude re-infection, especially if resection of the
infected material was incomplete. Few reports on surveil-
lance and prognosis after lower limb VGI exist. In a report of
66 cases, 13% had major limb amputation within 30 days
post-operatively regardless of location and type of
bypass.266 In another study of 37 cases of femoral VGI, the
re-infection rate was 12% and the long term limb salvage
rate was 86.5%.221
There are no scientific studies on the optimal surveillance
protocol. Surveillance after reconstruction should be close
until there are no signs of infection. Thereafter, routine
follow up visits should be done annually, including labora-
tory markers of infection and CT. Patients unfit for surgery
who are under conservative treatment and lifelong antibi-
otics should also be under continuous follow up. After the
acute situation has settled down, check up every three
months during the first year and every 6 e 12 months
thereafter if no sign of recurrent infection is seen, can be
performed.
Recommendation 49
For patients with peripheral vascular graft/endograft
infection, in situ reconstruction with autologous vein is
recommended if removal of the infected graft is likely to
lead to limb ischaemia.Class Level ReferencesI C Siracuse et al. (2013)221Recommendation 50
For patients with peripheral vascular graft/endograft
infection limited to only a part of the graft and in patients
unfit for surgery, local irrigation and/or negative pressure
wound therapy may be considered.Class Level ReferencesIIb C Thermann and Wollert
(2014),213 Andersson et al.
(2018),218 Monsen et al.
(2014)219Recommendation 51
For patients with a peripheral vascular graft/endograft
infection and a large tissue defect, negative pressure wound
therapy should be considered in order to promote wound
healing following infected graft removal and debridement
with or without vascular reconstruction.Class Level ReferencesIIa C Verma et al. (2015),215
Armstrong et al. (2007),216
Cheng et al. (2014)217
Andersson et al. (2018),218
Monsen et al. (2014)219
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For patients with peripheral vascular graft/endograft
infection, in situ reconstruction with cryopreserved
allografts should be considered as an alternative after
infected graft removal if it is likely to lead to limb ischaemia.Class Level ReferencesIIa C Lejay et al. (2017),147 Ehsan and
Gibbons (2009),223 Zetrenne et
al. (2007),225 Gabriel et al.
(2004),226 Verhelst et al.
(2004)227Recommendation 53
For patients with a peripheral vascular graft/endograft
infection and a large tissue defect, muscle or
musculocutaneous flaps should be considered to promote
groin healing following graft removal and debridement
with or without vascular reconstruction.Class Level ReferencesIIa B McMillan et al. (2012),237
Brewer et al. (2015),238
Mirzabeigi et al. (2017),244 Dua
et al. (2018)2469. PATIENTS’ PERSPECTIVES
Whatever the specialty in medicine, the treatment proposal
to a patient should be based on a clear, honest and informed
consent. The patient should be able to understand the bal-
ance between risks and benefits when a surgical procedure is
proposed to him/her. As vascular procedures require the use
of definitively implanted synthetic devices in the vast majority
of the cases, and because infection is a more threatened
complication following synthetic material implantation, the
risk of VGEI should clearly be explained to the patient.
9.1. Specific aspects
The following specifics of vascular procedures must be
considered from a patient perspective:
9.1.1. Pathological presentations. Vascular procedures are
performed either in an emergency setting for life or limb
threatening presentations, or for functional impairment or
prevention of arterial disease related complications. While
the risk of secondary infection is easily accepted in life or
limb threatening presentations, this is not the case in the
latter presentations.
9.1.2. Patient age and comorbidities. Vascular surgery
procedures are aimed at a specific population consisting of
older patients with a lot of cardiovascular, pulmonary, and
renal comorbidities. This particular frailty makes not only
secondary interventions more difficult to handle, but also
all the management, including imaging procedures with
iodine, or antimicrobial therapy.
9.1.3. The “easy” endovascular surgery. Currently, most
procedures are performed endovascularly in the era of
minimally invasive surgery and consequently open surgeryis performed less often. Even if endovascular surgery is a
less invasive modality, it must be presented as a treatment
option for a severe disease. Moreover, open surgery in the
setting of VGEI is more difficult than the initial procedure.
This should be explained to patients.
9.2. Patient feedback
9.2.1. Question 1: Did you feel your physician provided
enough information about the risk of infection at the time
of the initial procedure? Patients felt that not enough in-
formation was provided about the risk of infection: some
patients answered that they had not been informed about
the risk of infection, while others said that they had been
informed but did not understand what a VGEI meant. Some
patients had received antibiotic prophylaxis from general
physicians, while others had not.
Patients also stated that the the initial procedure was
performed in general hospitals, while re-intervention was
performed at university hospitals. Later daily care was
performed by general physicians lacking experience in
advanced knowledge of graft infections, stents, and so on.
9.2.2. Question 2: What did you think about the man-
agement once the diagnosis of VGEI was made? It seems
that the difficulty in obtaining a final diagnosis was generally
well understood by patients. They understood the necessity
of a complete microbiological and imaging work up. How-
ever, it has been pointed out that during the management,
the patient moved from one department to another, i.e.,
vascular surgery, infectious disease, and intensive care unit,
which impaired the relationship with a central physician.
Patients thought that management was lacking in structure,
and that a treatment algorithm was followed.
9.2.3. Question 3: Did you think your physician provided
enough information on the risks related to the VGEI?
Patients thought that they were not aware of the
complexity and seriousness of the situation. The majority of
patients did not anticipate the difficulties, the pain, or the
tiredness induced by the procedures. They mentioned that
they were not aware of the close follow up needed after re-
intervention.
9.3. Ways of improvement
To summarise, the following recommendations from a pa-
tient’s perspective could be suggested: (i) vascular surgeons
must provide more precise information on the risk of VGEI
whatever the procedure, even endovascular, and explain
precisely what VGEI means in terms of invasiveness; (ii)
there is a need to provide more education to general
practitioners on antibiotic prophylaxis measures, as well as
on when to suspect VGEI to make patients more confident
once out of the hospital e precise information about the
necessity for post-operative follow up screening is impor-
tant; (iii) physicians should be more aware of the need for a
referral physician to provide information on his/her status,
the evolution of the disease, and the next management
steps.
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The literature review performed to propose these ESVS
Guidelines on VGEI demonstrated a lack of robust evidence
in many aspects of VGEI management. The literature did not
provide enough RCTs, but mostly retrospective studies,
literature reviews, and some consensus articles. As a
consequence, most recommendations in these guidelines
have a low level of evidence, mostly level C. Even the
conclusions of papers, including large series, are debatable
for the following reasons:
 Populations are difficult to compare because of the
multiple clinical presentations, the different
microbiology protocols for micro-organism sampling and
studies, the different imaging modalities, and the
different management options in terms of antimicrobial
therapy duration, or choice of vascular substitutes.
 Large series proposing treatment modalities have mostly
been published by tertiary centres and most often favour
one technique over another. Consequently, there is a
high risk of bias related to only publishing positive results
while probably not reporting poorer experiences.
 Reviews and meta-analysis, potentially more valid than
series, could help in establishing valuable comparisons
between different management options. However, they
still have to be interpreted with caution because of the
previous comments on the potential heterogeneity of
the series they pooled.
Consequently, we conclude on the necessity to set up
large, multicentre registries that could include patients
prospectively with predefined variables allowing for valu-
able comparisons and conclusions. Such registries could be
the way to answer unresolved issues. Accordingly, the WC
proposes the following areas for research:
 The evaluation of the risk of brain abscesses in the
presentation of VGEI involving the SAT in order to
evaluate the potential emergency for management: This
major risk is often mentioned, but there are no reliable
data available on its incidence (see 5.1).
 The evaluation of the efficacy of EndoVAC therapy: this is
mandatory before extensive use, as to date results have
only been reported by one team (see 5.2.2).
 The efficacy of conservative treatment of VGEI with
drainage and irrigation: it is often presented as a
conservative alternative to direct graft explantation, but
there are no data reported, as in most series it is only
considered as a second line option in unfit patients (see
5.2.1, 6.2.1, 7.2.1, and 8.2.1).
 Evidence on the best antiseptic solutions for irrigation:
the literature and expert exchanges demonstrate there
is no strong evidence on the different choices in clinical
practice (see 4.1).
 Evidence on the efficacy of conservative treatment with
implantation of an abdominal or thoracic EG as a bridge:
this includes taking into consideration research on the
two previous points (see 6.2.2). The future role of imaging technologies, including bio-
optical imaging, which is a technology allowing
evaluation of biomaterials. The wide range of
morphological signs corresponding to the different VGEI
anatomical locations and clinical presentations requires
development of functional imaging. Bio-optical imaging
is a technology allowing evaluation of biomaterial
associated infections with highly sensitive cameras
enabling detection of very few photons from
bioluminescent or fluorescent sources inside the body
without the need of surgical intervention (see 2.8).
 Antibiotic prophylaxis for invasive manipulation in VGEI
carriers (see 3.2.2.2).
 Evidence on the optimal duration of antimicrobial
therapies: it is necessary to define the optimal
duration and type of antimicrobial treatment depending
on the clinical presentation, the anatomical location, and
the type of reconstruction, after VGEI according to
clinical, biological, and imaging follow up (see 4.1).
 Evidence on the best substitutes for ISR are still needed:
this includes clinical evidence of the best coating for an
infection resistant VG and evaluation of the risk of
microbiological mutation related to the use of a
rifampicin soaked VG. The actual risk of re-infection
depending on the materials must be evaluated. The
growing interest in the effectiveness of xenograft
materials for ISR must be evaluated and confirmed (see
6.2.2.2, 7.2.2.2, and 8.2.2.2).
 The best management of duodenal anastomosis, on site
or supramesocolic, for AEnF treated by ISR (see 7.3).
 The best management of infected aortic EG constructed
with suprarenal bare stents (see 7.2.6).
 The evaluation of secondary endovascular treatment of
an occluded superficial femoral artery in infected
femoro-popliteal bypass cases (see 8.2).
 The new products that are under evaluation: they
include biological extracellular patches such as the one
derived from porcine small intestinal mucosa, which
provides a biological scaffold for cellular ingrowth and
eventual tissue regeneration.
 Vascular tissue engineering is also at the forefront of its
translation into practice, as tissue engineered VG have
already been successfully implanted in children. There is a
high demand in other areas of vascular surgery for ideal
graft materials, such as for infection resistant conduits in
septic conditions. However, tissue engineered VG are not
ready for routine use as the quest for the ideal scaffold
materials, cell sources, and in vitro culturing conditions
continues. Further animal and clinical trials are required.APPENDIX AUTHORS’ AFFILIATIONS
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